Nicholas J White

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3304041/publications.pdf

Version: 2024-02-01

143 677 108,487 1,324 157 254 citations h-index g-index papers 1384 1384 1384 45905 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Artemisinin Resistance in <i>Plasmodium falciparum </i> Malaria. New England Journal of Medicine, 2009, 361, 455-467.	27.0	2,873
2	Spread of Artemisinin Resistance in <i>Plasmodium falciparum</i> Malaria. New England Journal of Medicine, 2014, 371, 411-423.	27.0	1,753
3	Typhoid Fever. New England Journal of Medicine, 2002, 347, 1770-1782.	27.0	1,357
4	Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature, 2001, 413, 848-852.	27.8	1,192
5	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	27.0	1,013
6	Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet, The, 2005, 366, 717-725.	13.7	973
7	Malaria. Lancet, The, 2014, 383, 723-735.	13.7	935
8	Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults. New England Journal of Medicine, 2004, 351, 1741-1751.	27.0	881
9	Antimalarial drug resistance. Journal of Clinical Investigation, 2004, 113, 1084-1092.	8.2	875
10	Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet, The, 2010, 376, 1647-1657.	13.7	809
11	Melioidosis. Lancet, The, 2003, 361, 1715-1722.	13.7	777
12	Qinghaosu (Artemisinin): The Price of Success. Science, 2008, 320, 330-334.	12.6	772
13	Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Lancet, The, 2012, 379, 1960-1966.	13.7	768
14	Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet, The, 2004, 364, 438-447.	13.7	707
15	Vivax Malaria: Neglected and Not Benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	675
16	Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nature Reviews Microbiology, 2006, 4, 272-282.	28.6	526
17	Melioidosis: A Major Cause of Community-Acquired Septicemia in Northeastern Thailand. Journal of Infectious Diseases, 1989, 159, 890-899.	4.0	515
18	Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature Genetics, 2015, 47, 226-234.	21.4	515

#	Article	IF	CITATIONS
19	Neurological manifestations of dengue infection. Lancet, The, 2000, 355, 1053-1059.	13.7	500
20	Artemisinin-Based Combination Treatment of Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 181-192.	1.4	495
21	Averting a malaria disaster. Lancet, The, 1999, 353, 1965-1967.	13.7	493
22	Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria Journal, 2011, 10, 297.	2.3	484
23	Qinghaosu. Lancet, The, 1993, 341, 603-608.	13.7	477
24	Artesunate combinations for treatment of malaria: meta-analysis. Lancet, The, 2004, 363, 9-17.	13.7	470
25	Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. BMC Medicine, 2019, 17, 1.	5.5	465
26	Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature, 2012, 487, 375-379.	27.8	450
27	Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	445
28	The Treatment of Malaria. New England Journal of Medicine, 1996, 335, 800-806.	27.0	443
29	Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet, The, 2000, 356, 297-302.	13.7	436
30	Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet, The, 2004, 363, 1764-1767.	13.7	432
31	Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nature Genetics, 2013, 45, 648-655.	21.4	424
32	Severe Hypoglycemia and Hyperinsulinemia in Falciparum Malaria. New England Journal of Medicine, 1983, 309, 61-66.	27.0	416
33	Effects of artemisinin derivatives on malaria transmissibility. Lancet, The, 1996, 347, 1654-1658.	13.7	409
34	Antimalarial Drug Toxicity. Drug Safety, 2004, 27, 25-61.	3.2	406
35	Comparison of Three Fluid Solutions for Resuscitation in Dengue Shock Syndrome. New England Journal of Medicine, 2005, 353, 877-889.	27.0	391
36	Antimalarial drug resistance and combination chemotherapy. Philosophical Transactions of the Royal Society B: Biological Sciences, 1999, 354, 739-749.	4.0	389

#	Article	IF	Citations
37	A Controlled Trial of Artemether or Quinine in Vietnamese Adults with Severe Falciparum Malaria. New England Journal of Medicine, 1996, 335, 76-83.	27.0	388
38	Estimation of the Total Parasite Biomass in Acute Falciparum Malaria from Plasma PfHRP2. PLoS Medicine, 2005, 2, e204.	8.4	371
39	The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion: a molecular epidemiology observational study. Lancet Infectious Diseases, The, 2017, 17, 491-497.	9.1	371
40	Independent Emergence of Artemisinin Resistance Mutations Among Plasmodium falciparum in Southeast Asia. Journal of Infectious Diseases, 2015, 211, 670-679.	4.0	368
41	Neurological sequelae of cerebral malaria in children. Lancet, The, 1990, 336, 1039-1043.	13.7	366
42	Early Origin and Recent Expansion of Plasmodium falciparum. Science, 2003, 300, 318-321.	12.6	365
43	Spread of artemisinin-resistant Plasmodium falciparum in Myanmar: a cross-sectional survey of the K13 molecular marker. Lancet Infectious Diseases, The, 2015, 15, 415-421.	9.1	363
44	Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance. Science, 2015, 347, 431-435.	12.6	362
45	The Prognostic and Pathophysiologic Role of Pro―and Antiinflammatory Cytokines in Severe Malaria. Journal of Infectious Diseases, 1999, 180, 1288-1297.	4.0	356
46	Effects of Plasmodium vivax malaria in pregnancy. Lancet, The, 1999, 354, 546-549.	13.7	347
47	A Quantitative Analysis of the Microvascular Sequestration of Malaria Parasites in the Human Brain. American Journal of Pathology, 1999, 155, 395-410.	3.8	340
48	A Major Genome Region Underlying Artemisinin Resistance in Malaria. Science, 2012, 336, 79-82.	12.6	334
49	Acute Management of Dengue Shock Syndrome: A Randomized Double-Blind Comparison of 4 Intravenous Fluid Regimens in the First Hour. Clinical Infectious Diseases, 2001, 32, 204-213.	5.8	332
50	Hemofiltration and Peritoneal Dialysis in Infection-Associated Acute Renal Failure in Vietnam. New England Journal of Medicine, 2002, 347, 895-902.	27.0	328
51	HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME. Lancet, The, 1989, 334, 697-701.	13.7	322
52	Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet, The, 2002, 360, 1287-1292.	13.7	319
53	Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease. Journal of the American College of Surgeons, 2009, 208, 341-347.	0.5	319
54	Quinoloneâ€ResistantSalmonella typhiin Viet Nam: Molecular Basis of Resistance and Clinical Response to Treatment. Clinical Infectious Diseases, 1997, 25, 1404-1410.	5.8	315

#	Article	IF	Citations
55	Plasmodium knowlesi: The Fifth Human Malaria Parasite. Clinical Infectious Diseases, 2008, 46, 172-173.	5.8	315
56	Two Nonrecombining Sympatric Forms of the Human Malaria Parasite <i>Plasmodium ovale</i> Occur Globally. Journal of Infectious Diseases, 2010, 201, 1544-1550.	4.0	310
57	Pharmacokinetics and Pharmacodynamics of Lumefantrine (Benflumetol) in Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2000, 44, 697-704.	3.2	308
58	Factors contributing to anemia after uncomplicated falciparum malaria American Journal of Tropical Medicine and Hygiene, 2001, 65, 614-622.	1.4	304
59	Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infectious Diseases, The, 2002, 2, 564-573.	9.1	301
60	Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2014, 14, 982-991.	9.1	300
61	Determinants of Mortality in a Combined Cohort of 501 Patients With HIV-Associated Cryptococcal Meningitis: Implications for Improving Outcomes. Clinical Infectious Diseases, 2014, 58, 736-745.	5.8	299
62	Cardiotoxicity of antimalarial drugs. Lancet Infectious Diseases, The, 2007, 7, 549-558.	9.1	296
63	Counterfeit anti-infective drugs. Lancet Infectious Diseases, The, 2006, 6, 602-613.	9.1	294
64	Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infectious Diseases, The, 2012, 12, 851-858.	9.1	294
65	Anaemia and malaria. Malaria Journal, 2018, 17, 371.	2.3	294
66	A Selective Sweep Driven by Pyrimethamine Treatment in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2003, 20, 1526-1536.	8.9	291
67	Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine. Clinical Pharmacokinetics, 1999, 37, 105-125.	3.5	283
68	Cardiac effects of antimalarial treatment with halofantrine. Lancet, The, 1993, 341, 1054-1056.	13.7	276
69	Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitology Today, 1996, 12, 399-401.	3.0	267
70	Relapses of Plasmodium vivax Infection Usually Result from Activation of Heterologous Hypnozoites. Journal of Infectious Diseases, 2007, 195, 927-933.	4.0	266
71	Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2006, 42, 1570-1577.	5. 8	258
72	Pharmacokinetics of Quinine, Chloroquine and Amodiaquine. Clinical Pharmacokinetics, 1996, 30, 263-299.	3.5	257

#	Article	IF	CITATIONS
73	Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet, The, 1998, 351, 1094-1097.	13.7	257
74	Mixed-species malaria infections in humans. Trends in Parasitology, 2004, 20, 233-240.	3.3	256
75	Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infectious Diseases, The, 2019, 19, 952-961.	9.1	252
76	Molecular Basis of Sequestration in Severe and Uncomplicated Plasmodium falciparum Malaria: Differential Adhesion of Infected Erythrocytes to CD36 and ICAM-I. Journal of Infectious Diseases, 1991, 164, 163-169.	4.0	250
77	Antimalarial drug resistance: the pace quickens. Journal of Antimicrobial Chemotherapy, 1992, 30, 571-585.	3.0	250
78	Plasmodium falciparum: In Vitro Studies of the Pharmacodynamic Properties of Drugs Used for the Treatment of Severe Malaria. Experimental Parasitology, 1993, 76, 85-95.	1.2	250
79	The epidemiology of severe malaria in an area of low transmission in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 256-262.	1.8	249
80	Malaria during pregnancy in an area of unstable endemicity. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 424-429.	1.8	248
81	Quantitation of Bacteria in Blood of Typhoid Fever Patients and Relationship between Counts and Clinical Features, Transmissibility, and Antibiotic Resistance. Journal of Clinical Microbiology, 1998, 36, 1683-1687.	3.9	247
82	The <i>pfmdr1</i> Gene Is Associated with a Multidrug-Resistant Phenotype in <i>Plasmodium falciparum</i> from the Western Border of Thailand. Antimicrobial Agents and Chemotherapy, 1999, 43, 2943-2949.	3.2	245
83	Fluid Replacement in Dengue Shock Syndrome: A Randomized, Doubleâ€Blind Comparison of Four Intravenousâ€Fluid Regimens. Clinical Infectious Diseases, 1999, 29, 787-794.	5.8	242
84	Genetic loci associated with delayed clearance of <i>Plasmodium falciparum</i> following artemisinin treatment in Southeast Asia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 240-245.	7.1	242
85	Genomic epidemiology of artemisinin resistant malaria. ELife, 2016, 5, .	6.0	242
86	The Global Threat of Counterfeit Drugs: Why Industry and Governments Must Communicate the Dangers. PLoS Medicine, 2005, 2, e100.	8.4	241
87	Artemisinin-based combination treatment of falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 181-92.	1.4	240
88	The Pathophysiology of Malaria. Advances in Parasitology, 1992, 31, 83-173.	3.2	238
89	Clinical Pharmacokinetics of Antimalarial Drugs. Clinical Pharmacokinetics, 1985, 10, 187-215.	3.5	236
90	Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malaria Journal, 2011, 10, 339.	2.3	236

#	Article	IF	Citations
91	The transcriptome of <i>Plasmodium vivax</i> reveals divergence and diversity of transcriptional regulation in malaria parasites. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16290-16295.	7.1	234
92	Evidence of blood-brain barrier dysfunction in human cerebral malaria. Neuropathology and Applied Neurobiology, 1999, 25, 331-340.	3.2	233
93	Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives American Journal of Tropical Medicine and Hygiene, 1999, 60, 547-555.	1.4	232
94	Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 67-73.	1.8	231
95	Quinine pharmacokinetics and toxicity in cerebral and uncomplicated falciparum malaria. American Journal of Medicine, 1982, 73, 564-572.	1.5	228
96	Treatment Of Multidrug-Resistant Plasmodium Falciparum Malaria With 3-Day Artesunate-Mefloquine Combination. Journal of Infectious Diseases, 1994, 170, 971-977.	4.0	228
97	Effect of Artemether-Lumefantrine Policy and Improved Vector Control on Malaria Burden in KwaZulu–Natal, South Africa. PLoS Medicine, 2005, 2, e330.	8.4	228
98	Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet, The, 1991, 337, 1140-1143.	13.7	225
99	Seizures and raised intracranial pressure in Vietnamese patients with Japanese encephalitis. Brain, 2002, 125, 1084-1093.	7.6	225
100	Dexamethasone in Vietnamese Adolescents and Adults with Bacterial Meningitis. New England Journal of Medicine, 2007, 357, 2431-2440.	27.0	221
101	The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. Lancet, The, 1996, 348, 219-223.	13.7	219
102	Evolution and expansion of multidrug-resistant malaria in southeast Asia: a genomic epidemiology study. Lancet Infectious Diseases, The, 2019, 19, 943-951.	9.1	219
103	Preventing antimalarial drug resistance through combinations. Drug Resistance Updates, 1998, 1, 3-9.	14.4	218
104	Respiratory Manifestations of Malaria. Chest, 2012, 142, 492-505.	0.8	215
105	The Relationship between Age and the Manifestations of and Mortality Associated with Severe Malaria. Clinical Infectious Diseases, 2008, 47, 151-157.	5.8	214
106	The Epidemiology of Melioidosis in Ubon Ratchatani, Northeast Thailand. International Journal of Epidemiology, 1994, 23, 1082-1090.	1.9	212
107	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
108	Risk factors for gametocyte carriage in uncomplicated falciparum malaria American Journal of Tropical Medicine and Hygiene, 1999, 60, 1019-1023.	1.4	212

#	Article	IF	CITATIONS
109	Direct In Vivo Assessment of Microcirculatory Dysfunction in Severe Falciparum Malaria. Journal of Infectious Diseases, 2008, 197, 79-84.	4.0	211
110	The epidemiology of malaria in a Karen population on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 105-111.	1.8	210
111	Fake antimalarials in Southeast Asia are a major impediment to malaria control: multinational cross-sectional survey on the prevalence of fake antimalarials. Tropical Medicine and International Health, 2004, 9, 1241-1246.	2.3	203
112	Fake artesunate in southeast Asia. Lancet, The, 2001, 357, 1948-1950.	13.7	202
113	Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIVâ€Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 Patients. Clinical Infectious Diseases, 2009, 49, 702-709.	5.8	201
114	Characterization of Solid Counterfeit Drug Samples by Desorption Electrospray Ionization and Direct-analysis-in-real-time Coupled to Time-of-flight Mass Spectrometry. ChemMedChem, 2006, 1, 702-705.	3.2	199
115	Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet, The, 2003, 361, 821-826.	13.7	197
116	Rickettsial Infections and Fever, Vientiane, Laos. Emerging Infectious Diseases, 2006, 12, 256-262.	4.3	197
117	Spiroindolone KAE609 for Falciparum and Vivax Malaria. New England Journal of Medicine, 2014, 371, 403-410.	27.0	197
118	HYPOGLYCAEMIA IN AFRICAN CHILDREN WITH SEVERE MALARIA. Lancet, The, 1987, 329, 708-711.	13.7	192
119	AN ULTRASTRUCTURAL STUDY OF THE BRAIN IN FATAL PLASMODIUM FALCIPARUM MALARIA. American Journal of Tropical Medicine and Hygiene, 2003, 69, 345-359.	1.4	192
120	The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Critical Care Medicine, 2000, 28, 1833-1840.	0.9	190
121	The assessment of antimalarial drug efficacy. Trends in Parasitology, 2002, 18, 458-464.	3.3	190
122	Central Role of the Spleen in Malaria Parasite Clearance. Journal of Infectious Diseases, 2002, 185, 1538-1541.	4.0	188
123	The Influence of HIV Infection on Clinical Presentation, Response to Treatment, and Outcome in Adults with Tuberculous Meningitis. Journal of Infectious Diseases, 2005, 192, 2134-2141.	4.0	188
124	Primaquine: the risks and the benefits. Malaria Journal, 2014, 13, 418.	2.3	188
125	The murine cerebral malaria phenomenon. Trends in Parasitology, 2010, 26, 11-15.	3.3	187
126	Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infectious Diseases, The, 2012, 12, 388-396.	9.1	186

#	Article	IF	Citations
127	The role of anti-malarial drugs in eliminating malaria. Malaria Journal, 2008, 7, S8.	2.3	185
128	Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial. Lancet, The, 2009, 373, 557-566.	13.7	185
129	Abnormal Blood Flow and Red Blood Cell Deformability in Severe Malaria. Parasitology Today, 2000, 16, 228-232.	3.0	184
130	Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study. Lancet Neurology, The, 2007, 6, 230-236.	10.2	182
131	Triple artemisinin-based combination therapies versus artemisinin-based combination therapies for uncomplicated Plasmodium falciparum malaria: a multicentre, open-label, randomised clinical trial. Lancet, The, 2020, 395, 1345-1360.	13.7	182
132	Clinical Features and Outcome of Severe Malaria in Gambian Children. Clinical Infectious Diseases, 1995, 21, 577-587.	5.8	181
133	High-Throughput Ultrasensitive Molecular Techniques for Quantifying Low-Density Malaria Parasitemias. Journal of Clinical Microbiology, 2014, 52, 3303-3309.	3.9	181
134	Intermittent Presumptive Treatment for Malaria. PLoS Medicine, 2005, 2, e3.	8.4	179
135	QUININE AND SEVERE FALCIPARUM MALARIA IN LATE PREGNANCY. Lancet, The, 1985, 326, 4-8.	13.7	178
136	Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nature Genetics, 2010, 42, 268-271.	21.4	178
137	Declining Efficacy of Artemisinin Combination Therapy Against <i>P. Falciparum</i> Malaria on the Thai–Myanmar Border (2003–2013): The Role of Parasite Genetic Factors. Clinical Infectious Diseases, 2016, 63, 784-791.	5.8	178
138	Red blood cell deformability as a predictor of anemia in severe falciparum malaria American Journal of Tropical Medicine and Hygiene, 1999, 60, 733-737.	1.4	177
139	Proinflammatory Cytokines and Chemokines in Humans with Japanese Encephalitis. Journal of Infectious Diseases, 2004, 190, 1618-1626.	4.0	174
140	The anaemia of Plasmodium vivax malaria. Malaria Journal, 2012, 11, 135.	2.3	173
141	Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor lla genes American Journal of Tropical Medicine and Hygiene, 2002, 67, 102-106.	1.4	171
142	The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread. FEMS Microbiology Reviews, 2017, 41, 34-48.	8.6	171
143	Dynamic Alteration in Splenic Function during Acute falciparum Malaria. New England Journal of Medicine, 1987, 317, 675-679.	27.0	170
144	Artemisinin Antimalarials in Pregnancy: A Prospective Treatment Study of 539 Episodes of Multidrugâ€Resistant <i>Plasmodium falciparum</i> . Clinical Infectious Diseases, 2001, 33, 2009-2016.	5.8	170

#	Article	IF	Citations
145	The evolution of drug–resistant malaria: the role of drug elimination half–life. Philosophical Transactions of the Royal Society B: Biological Sciences, 2002, 357, 505-519.	4.0	170
146	Reduced microcirculatory flow in severe falciparum malaria: pathophysiology and electron-microscopic pathology. Acta Tropica, 2004, 89, 309-317.	2.0	170
147	Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet, The, 1993, 341, 1044-1049.	13.7	169
148	Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nature Genetics, 2016, 48, 959-964.	21.4	169
149	Acute Renal Failure in Patients with Severe Falciparum Malaria. Clinical Infectious Diseases, 1992, 15, 874-880.	5.8	168
150	Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. Aids, 2009, 23, 701-706.	2.2	168
151	Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infectious Diseases, The, 2010, 10, 673-681.	9.1	168
152	Post-malaria neurological syndrome. Lancet, The, 1996, 348, 917-921.	13.7	167
153	Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Lancet, The, 1996, 348, 701-707.	13.7	167
154	Comparison of Imipenem and Ceftazidime as Therapy for Severe Melioidosis. Clinical Infectious Diseases, 1999, 29, 381-387.	5.8	167
155	A Dominant Clone of Leptospira interrogans Associated with an Outbreak of Human Leptospirosis in Thailand. PLoS Neglected Tropical Diseases, 2007, 1, e56.	3.0	167
156	Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria American Journal of Tropical Medicine and Hygiene, 1999, 60, 936-942.	1.4	167
157	Community-acquired bacterial bloodstream infections in developing countries in south and southeast Asia: a systematic review. Lancet Infectious Diseases, The, 2012, 12, 480-487.	9.1	166
158	Mefloquine Prophylaxis Prevents Malaria during Pregnancy: A Double-Blind, Placebo-Controlled Study. Journal of Infectious Diseases, 1994, 169, 595-603.	4.0	165
159	Therapeutic Responses to Different Antimalarial Drugs in Vivax Malaria. Antimicrobial Agents and Chemotherapy, 2000, 44, 1680-1685.	3.2	164
160	Strong HLA Class I–Restricted T Cell Responses in Dengue Hemorrhagic Fever: A Doubleâ€Edged Sword?. Journal of Infectious Diseases, 2001, 184, 1369-1373.	4.0	164
161	The epidemiology of subclinical malariaÂinfections in South-East Asia: findings from cross-sectional surveys in Thailand–Myanmar border areas, Cambodia, and Vietnam. Malaria Journal, 2015, 14, 381.	2.3	163
162	The Deformability of Red Blood Cells Parasitized by Plasmodium falciparumand P. vivax. Journal of Infectious Diseases, 2004, 189, 190-194.	4.0	162

#	Article	IF	Citations
163	Intraleucocytic malaria pigment and prognosis in severe malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 200-204.	1.8	161
164	Parasite Multiplication Potential and the Severity of Falciparum Malaria. Journal of Infectious Diseases, 2000, 181, 1206-1209.	4.0	161
165	Quantitation of Bacteria in Bone Marrow from Patients with Typhoid Fever: Relationship between Counts and Clinical Features. Journal of Clinical Microbiology, 2001, 39, 1571-1576.	3.9	161
166	Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet, The, 2004, 363, 18-22.	13.7	161
167	The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malaria Journal, 2009, 8, 31.	2.3	160
168	The parasite clearance curve. Malaria Journal, 2011, 10, 278.	2.3	160
169	Molecular mechanisms of cytoadherence in malaria. American Journal of Physiology - Cell Physiology, 1999, 276, C1231-C1242.	4.6	159
170	Clinical Pharmacokinetics of Mefloquine. Clinical Pharmacokinetics, 1990, 19, 264-279.	3.5	158
171	Randomized Comparison of Artemether-Benflumetol and Artesunate-Mefloquine in Treatment of MultidrugResistant Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 1998, 42, 135-139.	3.2	158
172	An Open, Randomized, Controlled Trial of Penicillin, Doxycycline, and Cefotaxime for Patients with Severe Leptospirosis. Clinical Infectious Diseases, 2004, 39, 1417-1424.	5.8	155
173	Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal, 2012, 11, 280.	2.3	155
174	Intrahost modeling of artemisinin resistance in <i>Plasmodium falciparum</i> . Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 397-402.	7.1	154
175	Natural History of Recurrent Urinary Tract Infections in Women. Clinical Infectious Diseases, 1991, 13, 77-84.	5.8	153
176	Axonal Injury in Cerebral Malaria. American Journal of Pathology, 2002, 160, 655-666.	3.8	152
177	Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet, The, 2006, 368, 1436-1443.	13.7	152
178	Guidelines for Field Surveys of the Quality of Medicines: A Proposal. PLoS Medicine, 2009, 6, e1000052.	8.4	152
179	Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malaria Journal, 2009, 8, 253.	2.3	151
180	Quinine Loading Dose in Cerebral Malaria *. American Journal of Tropical Medicine and Hygiene, 1983, 32, 1-5.	1.4	151

#	Article	IF	CITATIONS
181	Unidentified acids of strong prognostic significance in severe malaria*. Critical Care Medicine, 2004, 32, 1683-1688.	0.9	150
182	IFN- \hat{l}^3 at the Site of Infection Determines Rate of Clearance of Infection in Cryptococcal Meningitis. Journal of Immunology, 2005, 174, 1746-1750.	0.8	150
183	Malaria Burden and Artemisinin Resistance in the Mobile and Migrant Population on the Thai–Myanmar Border, 1999–2011: An Observational Study. PLoS Medicine, 2013, 10, e1001398.	8.4	150
184	Predicting the Clinical Outcome of Severe Falciparum Malaria in African Children: Findings From a Large Randomized Trial. Clinical Infectious Diseases, 2012, 54, 1080-1090.	5.8	148
185	ANTIMALARIAL DRUG RESISTANCE, ARTEMISININ-BASED COMBINATION THERAPY, AND THE CONTRIBUTION OF MODELING TO ELUCIDATING POLICY CHOICES. American Journal of Tropical Medicine and Hygiene, 2004, 71, 179-186.	1.4	148
186	Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infectious Diseases, The, 2016, 16, 61-69.	9.1	147
187	Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in Adults With Suspected Infection in Low- and Middle-Income Countries. JAMA - Journal of the American Medical Association, 2018, 319, 2202.	7.4	147
188	Intravenous Quinidine for the Treatment of Severe falciparum Malaria. New England Journal of Medicine, 1985, 312, 1273-1278.	27.0	146
189	Biochemical characteristics of clinical and environmental isolates of Burkholderia pseudomallei. Journal of Medical Microbiology, 1996, 45, 408-412.	1.8	146
190	Elevated Plasma Concentrations of Interferon (IFN)â€"γ and the IFNâ€Î³â€"Inducing Cytokines Interleukin (IL)â€"18, ILâ€12, and ILâ€15 in Severe Melioidosis. Journal of Infectious Diseases, 1999, 180, 1878-1885.	4.0	146
191	Effect of Antituberculosis Drug Resistance on Response to Treatment and Outcome in Adults with Tuberculous Meningitis. Journal of Infectious Diseases, 2005, 192, 79-88.	4.0	146
192	Manslaughter by Fake Artesunate in Asia—Will Africa Be Next?. PLoS Medicine, 2006, 3, e197.	8.4	141
193	Contrasting genetic structure in Plasmodium vivax populations from Asia and South America. International Journal for Parasitology, 2007, 37, 1013-1022.	3.1	140
194	Magnetic Resonance Imaging of the Brain in Patients with Cerebral Malaria. Clinical Infectious Diseases, 1995, 21, 300-309.	5.8	139
195	Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of piperaquine in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 862, 227-236.	2.3	139
196	Spurious Amplification of a <i>Plasmodium vivax</i> Small-Subunit RNA Gene by Use of Primers Currently Used To Detect <i>P. knowlesi</i> Journal of Clinical Microbiology, 2009, 47, 4173-4175.	3.9	139
197	A current perspective on antimicrobial resistance in Southeast Asia. Journal of Antimicrobial Chemotherapy, 2017, 72, 2963-2972.	3.0	139
198	Relation of the stage of parasite development in the peripheral blood to prognosis in severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 436-443.	1.8	138

#	Article	IF	CITATIONS
199	Circulating Red Cell–derived Microparticles in Human Malaria. Journal of Infectious Diseases, 2011, 203, 700-706.	4.0	138
200	Malaria parasite clearance. Malaria Journal, 2017, 16, 88.	2.3	138
201	The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. Journal of Antimicrobial Chemotherapy, 1989, 24, 295-309.	3.0	137
202	Activities of Artesunate and Primaquine againstAsexual- and Sexual-Stage Parasites in FalciparumMalaria. Antimicrobial Agents and Chemotherapy, 2004, 48, 1329-1334.	3.2	136
203	Relapse. Advances in Parasitology, 2012, 80, 113-150.	3.2	136
204	Spread of a single multidrug resistant malaria parasite lineage (PfPailin) to Vietnam. Lancet Infectious Diseases, The, 2017, 17, 1022-1023.	9.1	136
205	Persistence of Plasmodium falciparum HRP-2 in successfully treated acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 179-182.	1.8	135
206	Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics, 2011, 12, 391.	2.8	135
207	Sequestration and Microvascular Congestion Are Associated With Coma in Human Cerebral Malaria. Journal of Infectious Diseases, 2012, 205, 663-671.	4.0	134
208	Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2000, 44, 972-977.	3.2	133
209	Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet, The, 2006, 367, 2075-2085.	13.7	133
210	Antimalarial dosing regimens and drug resistance. Trends in Parasitology, 2008, 24, 127-134.	3.3	133
211	In Vivo Parasitological Measures of Artemisinin Susceptibility. Journal of Infectious Diseases, 2010, 201, 570-579.	4.0	133
212	Bed nets for the prevention of malaria and anaemia in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 620-626.	1.8	132
213	Artesunate/mefloquine treatment of multi-drug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 574-577.	1.8	132
214	HIGH RATE OF PLASMODIUM VIVAX RELAPSE FOLLOWING TREATMENT OF FALCIPARUM MALARIA IN THAILAND. Lancet, The, 1987, 330, 1052-1055.	13.7	131
215	Drugs for neglected diseases: a failure of the market and a public health failure?. Tropical Medicine and International Health, 2001, 6, 945-951.	2.3	131
216	Association of Genetic Mutations in Plasmodium vivax dhfr with Resistance to Sulfadoxine-Pyrimethamine: Geographical and Clinical Correlates. Antimicrobial Agents and Chemotherapy, 2001, 45, 3122-3127.	3.2	131

#	Article	IF	Citations
217	The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. European Journal of Clinical Pharmacology, 2003, 59, 545-552.	1.9	131
218	Artemisinin-based combinations. Current Opinion in Infectious Diseases, 2005, 18, 531-536.	3.1	131
219	Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. Lancet, The, 2018, 391, 1916-1926.	13.7	131
220	Prognostic Significance of Reduced Red Blood Cell Deformability in Severe Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1997, 57, 507-511.	1.4	131
221	Hemoglobin E: a balanced polymorphism protective against high parasitemias and thus severe P falciparum malaria. Blood, 2002, 100, 1172-1176.	1.4	130
222	Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam. Malaria Journal, 2017, 16, 27.	2.3	130
223	The Effects of Mefloquine Treatment in Pregnancy. Clinical Infectious Diseases, 1999, 28, 808-815.	5.8	129
224	Effects of Malaria during Pregnancy on Infant Mortality in an Area of Low Malaria Transmission. American Journal of Epidemiology, 2001, 154, 459-465.	3.4	129
225	A Longitudinal Study of Streptococcus pneumoniae Carriage in a Cohort of Infants and Their Mothers on the Thailand-Myanmar Border. PLoS ONE, 2012, 7, e38271.	2.5	129
226	Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1. Malaria Journal, 2005, 4, 20.	2.3	128
227	Primaquine to prevent transmission of falciparum malaria. Lancet Infectious Diseases, The, 2013, 13, 175-181.	9.1	128
228	COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. The Lancet Global Health, 2020, 8, e754-e755.	6.3	128
229	Toll-Like Receptor 2 Impairs Host Defense in Gram-Negative Sepsis Caused by Burkholderia pseudomallei (Melioidosis). PLoS Medicine, 2007, 4, e248.	8.4	128
230	Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malaria Journal, 2014, 13, 481.	2.3	127
231	THE EFFECTS OF PLASMODIUM FALCIPARUM AND P. VIVAX INFECTIONS ON PLACENTAL HISTOPATHOLOGY IN AN AREA OF LOW MALARIA TRANSMISSION. American Journal of Tropical Medicine and Hygiene, 2004, 70, 398-407.	1.4	127
232	Single-Nucleotide Polymorphism Alleles in the Insulin Receptor Gene Are Associated with Typical Migraine. Genomics, 2001, 78, 135-149.	2.9	126
233	Treatment of malaria: some considerations and limitations of the current methods of assessment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83, 767-777.	1.8	124
234	Novel Point Mutations in the Dihydrofolate Reductase Gene of Plasmodium vivax: Evidence for Sequential Selection by Drug Pressure. Antimicrobial Agents and Chemotherapy, 2003, 47, 1514-1521.	3.2	124

#	Article	IF	Citations
235	Risk Factors for Recurrent Melioidosis in Northeast Thailand. Clinical Infectious Diseases, 2006, 43, 979-986.	5.8	124
236	Biological Relevance of Colony Morphology and Phenotypic Switching by Burkholderia pseudomallei. Journal of Bacteriology, 2007, 189, 807-817.	2.2	124
237	High Heritability of Malaria Parasite Clearance Rate Indicates a Genetic Basis for Artemisinin Resistance in Western Cambodia. Journal of Infectious Diseases, 2010, 201, 1326-1330.	4.0	124
238	Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. Clinical Infectious Diseases, 2011, 52, 612-620.	5.8	124
239	MALARIA: New Developments in Treatment and Prevention. Annual Review of Medicine, 1999, 50, 179-192.	12.2	123
240	The de novo selection of drug–resistant malaria parasites. Proceedings of the Royal Society B: Biological Sciences, 2003, 270, 545-554.	2.6	123
241	Diagnosing Severe Falciparum Malaria in Parasitaemic African Children: A Prospective Evaluation of Plasma PfHRP2 Measurement. PLoS Medicine, 2012, 9, e1001297.	8.4	123
242	A Randomized Controlled Comparison of Azithromycin and Ofloxacin for Treatment of Multidrug-Resistant or Nalidixic Acid-Resistant Enteric Fever. Antimicrobial Agents and Chemotherapy, 2000, 44, 1855-1859.	3.2	122
243	The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density. Nature Communications, 2019, 10, 1433.	12.8	121
244	Isolation of Pseudomonas pseudomallei from soil in north-eastern Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 41-43.	1.8	120
245	A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy. PLoS Medicine, 2008, 5, e253.	8.4	120
246	Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: Divergent policies and practices in malaria endemic countries. PLoS Neglected Tropical Diseases, 2018, 12, e0006230.	3.0	120
247	A meta-analysis using individual patient data of trials comparing artemether with quinine in the treatment of severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 637-650.	1.8	119
248	Serology of Typhoid Fever in an Area of Endemicity and Its Relevance to Diagnosis. Journal of Clinical Microbiology, 2001, 39, 1002-1007.	3.9	119
249	Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil. European Journal of Clinical Pharmacology, 2003, 59, 553-557.	1.9	119
250	Deployment of Early Diagnosis and Mefloquine- Artesunate Treatment of Falciparum Malaria in Thailand: The Tak Malaria Initiative. PLoS Medicine, 2006, 3, e183.	8.4	119
251	How much fat is necessary to optimize lumefantrine oral bioavailability?. Tropical Medicine and International Health, 2007, 12, 195-200.	2.3	118
252	Lethal Malaria: Marchiafava and Bignami Were Right. Journal of Infectious Diseases, 2013, 208, 192-198.	4.0	118

#	Article	IF	Citations
253	Blood Stage Antimalarial Efficacy of Primaquine in Plasmodium vivax Malaria. Journal of Infectious Diseases, 1994, 169, 932-935.	4.0	117
254	A cohort study to assess the new WHO Japanese encephalitis surveillance standards. Bulletin of the World Health Organization, 2008, 86, 178-186.	3.3	117
255	Asymptomatic Natural Human Infections With the Simian Malaria Parasites <i>Plasmodium cynomolgi</i> and <i>Plasmodium knowlesi</i> Journal of Infectious Diseases, 2019, 219, 695-702.	4.0	117
256	Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 41-43.	1.8	116
257	Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology, 2002, 124, 247-263.	1.5	115
258	In vivo susceptibility of Plasmodium falciparum to artesunate in Binh Phuoc Province, Vietnam. Malaria Journal, 2012, 11, 355.	2.3	115
259	Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 324-327.	1.8	114
260	High-Dose Mefloquine in the Treatment of Multidrug-Resistant Falciparum Malaria. Journal of Infectious Diseases, 1992, 166, 1393-1400.	4.0	113
261	Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance. Antimicrobial Agents and Chemotherapy, 2000, 44, 3414-3424.	3.2	112
262	Soluble Granzymes Are Released during Human Endotoxemia and in Patients with Severe Infection Due to Gramâ€Negative Bacteria. Journal of Infectious Diseases, 2000, 182, 206-213.	4.0	112
263	The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2006, 62, 1021-1031.	1.9	112
264	Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with <i>Plasmodium falciparum</i> Malaria in Thailand. Antimicrobial Agents and Chemotherapy, 2008, 52, 1052-1061.	3.2	112
265	The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. Journal of Medical Microbiology, 1990, 33, 121-126.	1.8	111
266	Value of a Single-Tube Widal Test in Diagnosis of Typhoid Fever in Vietnam. Journal of Clinical Microbiology, 1999, 37, 2882-2886.	3.9	111
267	Fatal Plasmodium falciparum Malaria Causes Specific Patterns of Splenic Architectural Disorganization. Infection and Immunity, 2005, 73, 1986-1994.	2.2	111
268	Chloroqine Treatment of Severe Malaria in Children. New England Journal of Medicine, 1988, 319, 1493-1500.	27.0	110
269	Clinical features cannot predict a diagnosis of malaria or differentiate the infecting species in children living in an area of low transmission. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 45-49.	1.8	110
270	A Randomized, Doubleâ€Blind, Placeboâ€Controlled Trial of Acetazolamide for the Treatment of Elevated Intracranial Pressure in Cryptococcal Meningitis. Clinical Infectious Diseases, 2002, 35, 769-772.	5.8	110

#	Article	IF	Citations
271	The co-existence of Plasmodium: sidelights from falciparum and vivax malaria in Thailand. Trends in Parasitology, 2004, 20, 333-339.	3.3	110
272	How do patients use antimalarial drugs? A review of the evidence. Tropical Medicine and International Health, 2005, 10, 121-138.	2.3	110
273	Exploring the Contribution of Candidate Genes to Artemisinin Resistance in <i>Plasmodium falciparum (i). Antimicrobial Agents and Chemotherapy, 2010, 54, 2886-2892.</i>	3.2	110
274	Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common. Malaria Journal, 2012, 11, 418.	2.3	110
275	The duration of Plasmodium falciparum infections. Malaria Journal, 2014, 13, 500.	2.3	109
276	The hyaluronidase activities of some Southeast Asian snake venoms. Toxicon, 1988, 26, 629-637.	1.6	108
277	In Vivo Removal of Malaria Parasites From Red Blood Cells Without Their Destruction in Acute Falciparum Malaria. Blood, 1997, 90, 2037-2040.	1.4	108
278	Melioidosis in 6 Tsunami Survivors in Southern Thailand. Clinical Infectious Diseases, 2005, 41, 982-990.	5.8	108
279	Numerical Distributions of Parasite Densities During Asymptomatic Malaria. Journal of Infectious Diseases, 2016, 213, 1322-1329.	4.0	108
280	An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2003, 69, 345-59.	1.4	108
281	Serology and Carriage of Pseudomonas pseudomallei: A Prospective Study in 1000 Hospitalized Children in Northeast Thailand. Journal of Infectious Diseases, 1993, 167, 230-233.	4.0	107
282	A Randomized, Controlled Study of a Simple, Once-Daily Regimen of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated, Multidrug-Resistant Falciparum Malaria. Clinical Infectious Diseases, 2005, 41, 425-432.	5.8	107
283	Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ, The, 2013, 346, f3039-f3039.	6.0	107
284	The Mechanisms of Parasite Clearance after Antimalarial Treatment of <i>Plasmodium falciparum </i> Malaria. Journal of Infectious Diseases, 2000, 182, 629-633.	4.0	106
285	Sulfadoxine-pyrimethamine pharmacokinetics in malaria: Pediatric dosing implications. Clinical Pharmacology and Therapeutics, 2006, 80, 582-596.	4.7	106
286	Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens. PLoS Medicine, 2017, 14, e1002224.	8.4	106
287	The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review. BMC Medicine, 2018, 16, 200.	5.5	106
288	Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, The, 2019, 394, 929-938.	13.7	106

#	Article	IF	CITATIONS
289	Comparative Pharmacokinetics of Intramuscular Artesunate and Artemether in Patients with Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2004, 48, 4234-4239.	3.2	105
290	The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial. PLoS Medicine, 2019, 16, e1002745.	8.4	105
291	Binding of Quinine to Plasma Proteins in Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1985, 34, 681-686.	1.4	105
292	Randomized, Controlled Doseâ€Optimization Studies of Dihydroartemisininâ€Piperaquine for the Treatment of Uncomplicated Multidrugâ€Resistant Falciparum Malaria in Thailand. Journal of Infectious Diseases, 2004, 190, 1773-1782.	4.0	104
293	A quantitative ultrastructural study of renal pathology in fatal <i>Plasmodium falciparum</i> malaria. Tropical Medicine and International Health, 2007, 12, 1037-1050.	2.3	104
294	Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Medicine, 2016, 14, 79.	5.5	104
295	Ceftazidime vs. Amoxicillin/Clavulanate in the Treatment of Severe Melioidosis. Clinical Infectious Diseases, 1994, 19, 846-853.	5.8	103
296	Pathophysiology and Prognosis in Vietnamese Adults with Tuberculous Meningitis. Journal of Infectious Diseases, 2003, 188, 1105-1115.	4.0	103
297	A Randomized Comparison of Artesunateâ€Atovaquoneâ€Proguanil versus Quinine in Treatment for Uncomplicated Falciparum Malaria during Pregnancy. Journal of Infectious Diseases, 2005, 192, 846-853.	4.0	103
298	A Randomized Controlled Trial of Granulocyte Colony-Stimulating Factor for the Treatment of Severe Sepsis Due to Melioidosis in Thailand. Clinical Infectious Diseases, 2007, 45, 308-314.	5.8	103
299	Pharmacokinetic Determinants of the Window of Selection for Antimalarial Drug Resistance. Antimicrobial Agents and Chemotherapy, 2008, 52, 1589-1596.	3.2	103
300	Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia. BMC Infectious Diseases, 2015, 15, 511.	2.9	103
301	The activation of vivax malaria hypnozoites by infectious diseases. Lancet Infectious Diseases, The, 2013, 13, 900-906.	9.1	102
302	Artemisinin resistance – modelling the potential human and economic costs. Malaria Journal, 2014, 13, 452.	2.3	102
303	Development of temporal modelling for forecasting and prediction of malaria infections using time-series and ARIMAX analyses: A case study in endemic districts of Bhutan. Malaria Journal, 2010, 9, 251.	2.3	101
304	The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study. Lancet Infectious Diseases, The, 2018, 18, 565-572.	9.1	101
305	Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 689-693.	1.8	100
306	N-acetylcysteine as adjunctive treatment in severe malaria: A randomized, double-blinded placebo-controlled clinical trial*. Critical Care Medicine, 2009, 37, 516-522.	0.9	100

#	Article	IF	Citations
307	Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. Lancet Infectious Diseases, The, 2014, 14, 130-139.	9.1	100
308	Retinal Hemorrhage, A Common Sign of Prognostic Significance in Cerebral Malaria *. American Journal of Tropical Medicine and Hygiene, 1983, 32, 911-915.	1.4	100
309	Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 651-656.	1.8	99
310	Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2015, 59, 7224-7231.	3.2	99
311	Artemisinin resistance without pfkelch13 mutations in Plasmodium falciparum isolates from Cambodia. Malaria Journal, 2017, 16, 195.	2.3	99
312	Antimalarial pharmacokinetics and treatment regimens British Journal of Clinical Pharmacology, 1992, 34, 1-10.	2.4	98
313	Activation of the coagulation cascade in severe falciparum malaria through the intrinsic pathway. British Journal of Haematology, 1994, 87, 100-105.	2.5	98
314	Access to artemisinin combination therapy for malaria in remote areas of Cambodia. Malaria Journal, 2008, 7, 96.	2.3	98
315	Acute Suppurative Parotitis Caused by Pseudomonas pseudomallei in Children. Journal of Infectious Diseases, 1989, 159, 654-660.	4.0	97
316	Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 517-524.	1.8	97
317	Microsatellite Variation, Repeat Array Length, and Population History of Plasmodium vivax. Molecular Biology and Evolution, 2006, 23, 1016-1018.	8.9	97
318	Glyburide Is Anti-inflammatory and Associated with Reduced Mortality in Melioidosis. Clinical Infectious Diseases, 2011, 52, 717-725.	5.8	97
319	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
320	Disposition of oral quinine in acute falciparum malaria. European Journal of Clinical Pharmacology, 1991, 40, 49-52.	1.9	96
321	Quantitative recovery of Burkholderia pseudomallei from soil in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 488-490.	1.8	96
322	The Clinical Benefit of Adjunctive Dexamethasone in Tuberculous Meningitis Is Not Associated with Measurable Attenuation of Peripheral or Local Immune Responses. Journal of Immunology, 2005, 175, 579-590.	0.8	96
323	Population Pharmacokinetics of Lumefantrine in Pregnant Women Treated with Artemether-Lumefantrine for Uncomplicated <i>Plasmodium falciparum</i> Malaria. Antimicrobial Agents and Chemotherapy, 2009, 53, 3837-3846.	3.2	96
324	In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up. Antimicrobial Agents and Chemotherapy, 2004, 48, 4271-4280.	3.2	95

#	Article	IF	CITATIONS
325	Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2006, 62, 367-371.	1.9	95
326	Obstetric ultrasound scanning by local health workers in a refugee camp on the Thai–Burmese border. Ultrasound in Obstetrics and Gynecology, 2009, 34, 395-403.	1.7	95
327	Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrobial Agents and Chemotherapy, 1994, 38, 1716-1720.	3.2	94
328	A review of the spectrum of clinical ocular fundus findings in P. falciparum malaria in African children with a proposed classification and grading system. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 619-622.	1.8	94
329	Red cell selectivity in malaria: a study of multiple-infected erythrocytes. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 165-168.	1.8	94
330	Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Tropica, 2005, 94, 230-240.	2.0	94
331	Increased Gametocytemia after Treatment: An Early Parasitological Indicator of Emerging Sulfadoxineâ€Pyrimethamine Resistance in Falciparum Malaria. Journal of Infectious Diseases, 2008, 197, 1605-1613.	4.0	94
332	Molecular epidemiology of resistance to antimalarial drugs in the Greater Mekong subregion: an observational study. Lancet Infectious Diseases, The, 2020, 20, 1470-1480.	9.1	94
333	Comparison of Conventional Bacteriology with Nucleic Acid Amplification (Amplified Mycobacterium) Tj ETQq1 1 (Chemotherapy. Journal of Clinical Microbiology, 2004, 42, 996-1002.	0.784314 i 3.9	rgBT /Overlo 93
334	Rapid Diagnosis of Japanese Encephalitis by Using an Immunoglobulin M Dot Enzyme Immunoassay. Journal of Clinical Microbiology, 1998, 36, 2030-2034.	3.9	93
335	Quinine and Quinidine. Journal of Cardiovascular Pharmacology, 1983, 5, 173-175.	1.9	92
336	Prognostic Value of Cytokine Concentrations (Tumor Necrosis Factor–α, Interleukinâ€6, and) Tj ETQq0 0 0 rgB 621-625.	T /Overlock 4.0	k 10 Tf 50 3 92
337	Evaluation of the World Health Organization standard tourniquet test and a modified tourniquet test in the diagnosis of dengue infection in Viet Nam. Tropical Medicine and International Health, 2002, 7, 125-132.	2.3	92
338	Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2009, 53, 945-952.	3.2	92
339	Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 430-433.	1.8	91
340	Safety and Efficacy of Dihydroartemisinin-Piperaquine in Falciparum Malaria: A Prospective Multi-Centre Individual Patient Data Analysis. PLoS ONE, 2009, 4, e6358.	2.5	91
341	Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 660-664.	1.8	90
342	Artemisinin resistanceâ€"the clock is ticking. Lancet, The, 2010, 376, 2051-2052.	13.7	90

#	Article	IF	CITATIONS
343	The Primacy of Public Health Considerations in Defining Poor Quality Medicines. PLoS Medicine, 2011, 8, e1001139.	8.4	90
344	Artesunate versus artemether in combination with mefloquine for the treatment of multidrug-resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 523-527.	1.8	89
345	A Simple Score to Predict the Outcome of Severe Malaria in Adults. Clinical Infectious Diseases, 2010, 50, 679-685.	5.8	89
346	Antimalarial Activity of KAF156 in Falciparum and Vivax Malaria. New England Journal of Medicine, 2016, 375, 1152-1160.	27.0	89
347	CAUSES OF COMMUNITY-ACQUIRED BACTEREMIA AND PATTERNS OF ANTIMICROBIAL RESISTANCE IN VIENTIANE, LAOS. American Journal of Tropical Medicine and Hygiene, 2006, 75, 978-985.	1.4	89
348	A Comparison of Chloramphenicol, Trimethoprimâ€Sulfamethoxazole, and Doxycycline with Doxycycline Alone as Maintenance Therapy for Melioidosis. Clinical Infectious Diseases, 1999, 29, 375-380.	5.8	88
349	Febrile temperatures induce cytoadherence of ring-stage Plasmodium falciparum-infected erythrocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 11825-11829.	7.1	88
350	Beri-beri: the major cause of infant mortality in Karen refugees. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 251-255.	1.8	88
351	Molecular Analysis of incHI1 Antimicrobial Resistance Plasmids from Salmonella Serovar Typhi Strains Associated with Typhoid Fever. Antimicrobial Agents and Chemotherapy, 2003, 47, 2732-2739.	3.2	88
352	Efficacy and safety of dihydroartemisinin-piperaquine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 858-866.	1.8	88
353	Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrugâ€resistant falciparum malaria. Tropical Medicine and International Health, 2007, 12, 201-208.	2.3	88
354	<i>Plasmodium falciparum pfmdr$1> Amplification, Mefloquine Resistance, and Parasite Fitness. Antimicrobial Agents and Chemotherapy, 2009, 53, 1509-1515.$</i>	3.2	88
355	Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1997-2007.	3.2	88
356	Management of relapsing <i>Plasmodium vivax </i> malaria. Expert Review of Anti-Infective Therapy, 2016, 14, 885-900.	4.4	88
357	Cardiovascular toxicity and distribution kinetics of intravenous chloroquine British Journal of Clinical Pharmacology, 1986, 22, 31-36.	2.4	87
358	Spread of anti-malarial drug resistance: Mathematical model with implications for ACT drug policies. Malaria Journal, 2008, 7, 229.	2.3	87
359	Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2017, 34, 131-144.	8.9	87
360	Function of the Blood-Cerebrospinal Fluid Barrier in Human Cerebral Malaria: Rejection of the Permeability Hypothesis. American Journal of Tropical Medicine and Hygiene, 1986, 35, 882-889.	1.4	87

#	Article	IF	Citations
361	Studies of the neurotoxicity of oral artemisinin derivatives in mice American Journal of Tropical Medicine and Hygiene, 2000, 62, 409-412.	1.4	87
362	The effects of multiplication and synchronicity on the vascular distribution of parasites in falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 590-597.	1.8	86
363	The Dynamics of Drug Action on the Within-host Population Growth of Infectious Agents: Melding Pharmacokinetics with Pathogen Population Dynamics. Journal of Theoretical Biology, 1998, 194, 313-339.	1.7	86
364	Postpartum thiamine deficiency in a Karen displaced population. American Journal of Clinical Nutrition, 2001, 74, 808-813.	4.7	86
365	Fast detection and identification of counterfeit antimalarial tablets by Raman spectroscopy. Journal of Raman Spectroscopy, 2007, 38, 181-187.	2.5	86
366	The Effect of Dosing Regimens on the Antimalarial Efficacy of Dihydroartemisinin-Piperaquine: A Pooled Analysis of Individual Patient Data. PLoS Medicine, 2013, 10, e1001564.	8.4	86
367	Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review. Malaria Journal, 2016, 15, 523.	2.3	86
368	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. PLoS Medicine, 2020, 17, e1003252.	8.4	86
369	Assessment of the neurotoxicity of parenteral artemisinin derivatives in mice American Journal of Tropical Medicine and Hygiene, 1998, 59, 519-522.	1.4	86
370	A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria American Journal of Tropical Medicine and Hygiene, 2000, 62, 65-69.	1.4	86
371	Hypoglycaemia and antimalarial drugs: quinidine and release of insulin BMJ: British Medical Journal, 1986, 292, 1319-1321.	2.3	85
372	Plasmepsin II–III copy number accounts for bimodal piperaquine resistance among Cambodian Plasmodium falciparum. Nature Communications, 2018, 9, 1769.	12.8	85
373	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	9.1	85
374	Transmission intensity and Plasmodium falciparum diversity on the northwestern border of Thailand American Journal of Tropical Medicine and Hygiene, 1998, 58, 195-203.	1.4	85
375	Dyserythropoiesis and ineffective erythropoiesis in <i>Plasmodium vivax</i> malaria. British Journal of Haematology, 1989, 72, 91-99.	2.5	84
376	Open-Label Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Doxycycline, and Chloramphenicol Compared with Trimethoprim-Sulfamethoxazole and Doxycycline for Maintenance Therapy of Melioidosis. Antimicrobial Agents and Chemotherapy, 2005, 49, 4020-4025.	3.2	84
377	Primaquine-induced haemolysis in females heterozygous for G6PD deficiency. Malaria Journal, 2018, 17, 101.	2.3	84
378	A comparative study of ofloxacin and cefixime for treatment of typhoid fever in children. Pediatric Infectious Disease Journal, 1999, 18, 245-248.	2.0	84

#	Article	IF	CITATIONS
379	Endogenous Interleukin-10 Modulates Proinflammatory Response in Plasmodium falciparum Malaria. Journal of Infectious Diseases, 1998, 178, 520-525.	4.0	83
380	Noninvasive Measurement of Microvascular Leakage in Patients with Dengue Hemorrhagic Fever. Clinical Infectious Diseases, 2001, 32, 243-253.	5.8	83
381	Malaria and the lung. Clinics in Chest Medicine, 2002, 23, 457-468.	2.1	83
382	Population Pharmacokinetics and Pharmacodynamics of Piperaquine in Children With Uncomplicated Falciparum Malaria. Clinical Pharmacology and Therapeutics, 2012, 91, 497-505.	4.7	83
383	Prognostic Significance of Quantitative Bacteremia in Septicemic Melioidosis. Clinical Infectious Diseases, 1995, 21, 1498-1500.	5 . 8	82
384	Population pharmacokinetics of mefloquine in patients with acute falciparum malaria. Clinical Pharmacology and Therapeutics, 1999, 66, 472-484.	4.7	82
385	Pharmacokinetic and Pharmacodynamic Considerations in Antimalarial Dose Optimization. Antimicrobial Agents and Chemotherapy, 2013, 57, 5792-5807.	3.2	82
386	Clinical correlates of in vitro Plasmodium falciparum cytoadherence. Infection and Immunity, 1991, 59, 873-878.	2.2	82
387	A prospective comparison of co-amoxiclav and the combination of chloramphenicol, doxycycline, and co-trimoxazole for the oral maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 546-549.	1.8	81
388	Elevated Serum Procalcitonin Levels in Patients with Melioidosis. Clinical Infectious Diseases, 1995, 20, 641-645.	5.8	81
389	Randomized Comparison of Artesunate and Quinine in the Treatment of Severe Falciparum Malaria. Clinical Infectious Diseases, 2003, 37, 7-16.	5.8	81
390	Comparison of artemether and chloroquine for severe malaria in Gambian children. Lancet, The, 1992, 339, 317-321.	13.7	80
391	Artemisinin: current status. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 3-4.	1.8	80
392	Rosette formation by Plasmodium vivax. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 635-637.	1.8	80
393	Transmission-Blocking Activities of Quinine, Primaquine, and Artesunate. Antimicrobial Agents and Chemotherapy, 2006, 50, 1927-1930.	3.2	80
394	QUINIDINE IN FALCIPARUM MALARIA. Lancet, The, 1981, 318, 1069-1071.	13.7	79
395	Alpha 1â€acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria British Journal of Clinical Pharmacology, 1991, 32, 311-315.	2.4	79
396	Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. British Journal of Clinical Pharmacology, 1996, 42, 599-604.	2.4	79

#	Article	IF	Citations
397	A Clinical, Microbiological, and Pathological Study of Intestinal Perforation Associated with Typhoid Fever. Clinical Infectious Diseases, 2004, 39, 61-67.	5.8	79
398	Optimising Strategies for Plasmodium falciparum Malaria Elimination in Cambodia: Primaquine, Mass Drug Administration and Artemisinin Resistance. PLoS ONE, 2012, 7, e37166.	2.5	79
399	Antimalarial Drugs Reduce Cytoadherence and Rosetting of Plasmodium falciparum. Journal of Infectious Diseases, 1996, 173, 691-698.	4.0	78
400	Trimethoprim/sulfamethoxazole resistance in clinical isolates of Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy, 2005, 55, 1029-1031.	3.0	78
401	A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malaria Journal, 2005, 4, 46.	2.3	78
402	The First Plasmodium vivax Relapses of Life Are Usually Genetically Homologous. Journal of Infectious Diseases, 2012, 205, 680-683.	4.0	78
403	Fluid Resuscitation of Adults With Severe Falciparum Malaria. Critical Care Medicine, 2013, 41, 972-981.	0.9	78
404	Pharmacokinetic Interactions between Primaquine and Chloroquine. Antimicrobial Agents and Chemotherapy, 2014, 58, 3354-3359.	3.2	78
405	Host immunity to <i>Plasmodium falciparum</i> and the assessment of emerging artemisinin resistance in a multinational cohort. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3515-3520.	7.1	78
406	Clinical and neurophysiological study of the effects of multiple doses of artemisinin on brain-stem function in Vietnamese patients American Journal of Tropical Medicine and Hygiene, 2000, 63, 48-55.	1.4	78
407	The effects of Plasmodium falciparum and P. vivax infections on placental histopathology in an area of low malaria transmission. American Journal of Tropical Medicine and Hygiene, 2004, 70, 398-407.	1.4	78
408	Erythrocyte survival in severe falciparum malaria. Acta Tropica, 1991, 48, 263-270.	2.0	77
409	Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1094-1099.	1.4	77
410	Two or three days of ofloxacin treatment for uncomplicated multidrug-resistant typhoid fever in children. Antimicrobial Agents and Chemotherapy, 1996, 40, 958-961.	3.2	76
411	Mefloquine in infants and young children. Annals of Tropical Paediatrics, 1996, 16, 281-286.	1.0	76
412	Comparison of artemisinin suppositories, intramuscular artesunate and intravenous quinine for the treatment of severe childhood malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 335-342.	1.8	76
413	Murder by fake drugs. BMJ: British Medical Journal, 2002, 324, 800-801.	2.3	76
414	Simplified antimalarial therapeutic monitoring: using the day-7 drug level?. Trends in Parasitology, 2008, 24, 159-163.	3.3	76

#	Article	IF	CITATIONS
415	Defining Falciparum-Malaria-Attributable Severe Febrile Illness in Moderate-to-High Transmission Settings on the Basis of Plasma PfHRP2 Concentration. Journal of Infectious Diseases, 2013, 207, 351-361.	4.0	76
416	Characterization of G6PD Genotypes and Phenotypes on the Northwestern Thailand-Myanmar Border. PLoS ONE, 2014, 9, e116063.	2.5	76
417	Drug treatment and prevention of malaria. European Journal of Clinical Pharmacology, 1988, 34, 1-14.	1.9	75
418	Semi-quantitative measurement of Plasmodium falciparum antigen PfHRP2 in blood and plasma. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 479-483.	1.8	75
419	Two Randomized Controlled Trials of Ceftazidime Alone versus Ceftazidime in Combination with Trimethoprim-Sulfamethoxazole for the Treatment of Severe Melioidosis. Clinical Infectious Diseases, 2005, 41, 1105-1113.	5.8	75
420	Parenteral Chloroquine for Treating Falciparum Malaria. Journal of Infectious Diseases, 1987, 155, 192-201.	4.0	74
421	Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Critical Care Medicine, 2000, 28, 1353-1362.	0.9	74
422	Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria. Acta Tropica, 2004, 89, 351-356.	2.0	74
423	Genetic diversity of Plasmodium vivax in Kolkata, India. Malaria Journal, 2006, 5, 71.	2.3	74
424	Development and validation of a liquid chromatographic–tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 74-83.	2.3	74
425	Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malaria Journal, 2008, 7, 249.	2.3	74
426	Gene Amplification of the Multidrug Resistance 1 Gene of Plasmodium vivax Isolates from Thailand, Laos, and Myanmar. Antimicrobial Agents and Chemotherapy, 2008, 52, 2657-2659.	3.2	74
427	Spatial and temporal epidemiology of clinical malaria in Cambodia 2004–2013. Malaria Journal, 2014, 13, 385.	2.3	74
428	The effect of dose on the antimalarial efficacy of artemether–lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infectious Diseases, The, 2015, 15, 692-702.	9.1	74
429	Antimalarial drug resistance. Journal of Clinical Investigation, 2004, 113, 1084-1092.	8.2	74
430	Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study British Journal of Clinical Pharmacology, 1990, 30, 79-85.	2.4	73
431	Penicillin vs. Erythromycin in the Treatment of Diphtheria. Clinical Infectious Diseases, 1998, 27, 845-850.	5.8	73
432	Nonrandom Distribution of Burkholderia pseudomallei Clones in Relation to Geographical Location and Virulence. Journal of Clinical Microbiology, 2006, 44, 2553-2557.	3.9	73

#	Article	IF	Citations
433	The role of simple mathematical models in malaria elimination strategy design. Malaria Journal, 2009, 8, 212.	2.3	72
434	Complex Interactions between Soil-Transmitted Helminths and Malaria in Pregnant Women on the Thai-Burmese Border. PLoS Neglected Tropical Diseases, 2010, 4, e887.	3.0	72
435	Cell-free hemoglobin mediated oxidative stress is associated with acute kidney injury and renal replacement therapy in severe falciparum malaria: an observational study. BMC Infectious Diseases, 2017, 17, 313.	2.9	72
436	Neuropathologic toxicity of artemisinin derivatives in a mouse model American Journal of Tropical Medicine and Hygiene, 2002, 67, 423-429.	1.4	72
437	Treatment of vivax malaria on the western border of Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 433-438.	1.8	71
438	Thiamine deficiency and malaria in adults from southeast Asia. Lancet, The, 1999, 353, 546-549.	13.7	71
439	Pulmonary Manifestations of Malaria. Treatments in Respiratory Medicine, 2006, 5, 419-428.	1.4	71
440	Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial. Clinical Infectious Diseases, 2011, 53, 977-984.	5.8	71
441	Effect of Early Detection and Treatment on Malaria Related Maternal Mortality on the North-Western Border of Thailand 1986–2010. PLoS ONE, 2012, 7, e40244.	2.5	71
442	Safety and effectiveness of mass drug administration to accelerate elimination of artemisinin-resistant falciparum malaria: A pilot trial in four villages of Eastern Myanmar. Wellcome Open Research, 2017, 2, 81.	1.8	71
443	Short Course of Ofloxacin for Treatment of Multidrug-Resistant Typhoid. Clinical Infectious Diseases, 1995, 20, 917-923.	5.8	70
444	Treatment of Uncomplicated Multidrugâ€Resistant Falciparum Malaria with Artesunateâ€Atovaquoneâ€Proguanil. Clinical Infectious Diseases, 2002, 35, 1498-1504.	5.8	70
445	Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Molecular and Biochemical Parasitology, 2002, 119, 63-73.	1.1	70
446	Chloroquine prophylaxis against vivax malaria in pregnancy: a randomized, doubleâ€blind, placeboâ€controlled trial. Tropical Medicine and International Health, 2007, 12, 209-218.	2.3	70
447	The effect of insecticide-treated bed nets on the incidence and prevalence of malaria in children in an area of unstable seasonal transmission in western Myanmar. Malaria Journal, 2013, 12, 363.	2.3	70
448	Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nature Communications, 2019, 10, 5595.	12.8	70
449	Plasmodium vivax Adherence to Placental Glycosaminoglycans. PLoS ONE, 2012, 7, e34509.	2.5	70
450	A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. Journal of Pharmaceutical and Biomedical Analysis, 2000, 24, 65-70.	2.8	69

#	Article	IF	CITATIONS
451	The CXC Chemokines Gamma Interferon (IFN-γ)-Inducible Protein 10 and Monokine Induced by IFN-γ Are Released during Severe Melioidosis. Infection and Immunity, 2000, 68, 3888-3893.	2.2	69
452	Community-acquired septicaemia in southern Viet Nam: the importance of multidrug-resistant Salmonella typhi. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 503-508.	1.8	68
453	Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2002, 46, 778-782.	3.2	68
454	Destabilisation and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem products. European Journal of Haematology, 2005, 74, 324-332.	2.2	68
455	Single day mefloquine-artesunate combination in the treatment of multi-drug resistant falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 213-217.	1.8	67
456	Randomized Comparison of Chloroquine plus Sulfadoxine-Pyrimethamine versus Artesunate plus Mefloquine versus Artemether-Lumefantrine in the Treatment of Uncomplicated Falciparum Malaria in the Lao People's Democratic Republic. Clinical Infectious Diseases, 2004, 39, 1139-1147.	5.8	67
457	A systematic overview of published antimalarial drug trials. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 73-81.	1.8	67
458	Activation of the Coagulation Cascade in Patients with Leptospirosis. Clinical Infectious Diseases, 2008, 46, 254-260.	5 . 8	67
459	The spectrum of retinopathy in adults with Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, 665-671.	1.8	67
460	Antimicrobial susceptibility of bacterial isolates from community acquired infections in Subâ€saharan Africa and Asian low and middle income countries. Tropical Medicine and International Health, 2011, 16, 1167-1179.	2.3	67
461	Mass primaquine treatment to eliminate vivax malaria: lessons from the past. Malaria Journal, 2014, 13, 51.	2.3	67
462	Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infectious Diseases, The, 2016, 16, 576-583.	9.1	67
463	Therapy for Women Hospitalized with Acute Pyelonephritis: A Randomized Trial of Ampicillin versus Trimethoprim-Sulfamethoxazole for 14 Days. Journal of Infectious Diseases, 1991, 163, 325-330.	4.0	66
464	A study of the factors affecting the metabolic clearance of quinine in malaria. European Journal of Clinical Pharmacology, 1997, 52, 487-493.	1.9	66
465	The Clinical Significance of Cerebrospinal Fluid Levels of Kynurenine Pathway Metabolites and Lactate in Severe Malaria. Journal of Infectious Diseases, 2002, 185, 650-656.	4.0	66
466	The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 180-184.	1.8	66
467	No evidence of cardiotoxicity during antimalarial treatment with artemether-lumefantrine American Journal of Tropical Medicine and Hygiene, 1999, 61, 964-967.	1.4	66
468	Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria British Journal of Clinical Pharmacology, 1986, 21, 677-683.	2.4	65

#	Article	IF	CITATIONS
469	Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza. PLoS ONE, 2008, 3, e3410.	2.5	65
470	Staphylococcus aureus Bacteraemia in a Tropical Setting: Patient Outcome and Impact of Antibiotic Resistance. PLoS ONE, 2009, 4, e4308.	2.5	65
471	Surveillance of Artemisinin Resistance in Plasmodium falciparum in India Using the kelch13 Molecular Marker. Antimicrobial Agents and Chemotherapy, 2015, 59, 2548-2553.	3.2	65
472	The threat of antimalarial drug resistance. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 10.	2.2	65
473	New insights into the Plasmodium vivax transcriptome using RNA-Seq. Scientific Reports, 2016, 6, 20498.	3.3	65
474	Diagnosis and Treatment of <i>Plasmodium vivax</i> Malaria. American Journal of Tropical Medicine and Hygiene, 2016, 95, 35-51.	1.4	65
475	n-vitro activity of carbapenem antibiotics against \hat{l}^2 -lactam susceptible and resistant strains of Burkholderia pseudomallei. Journal of Antimicrobial Chemotherapy, 1996, 37, 611-615.	3.0	64
476	Therapeutic Responses to Quinine and Clindamycin in Multidrug-Resistant Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2000, 44, 2395-2398.	3.2	64
477	Differential Antibioticâ€Induced Endotoxin Release in Severe Melioidosis. Journal of Infectious Diseases, 2000, 181, 1014-1019.	4.0	64
478	Optimization of Culture of Leptospira from Humans with Leptospirosis. Journal of Clinical Microbiology, 2007, 45, 1363-1365.	3.9	64
479	Relative Contributions of Macrovascular and Microvascular Dysfunction to Disease Severity in Falciparum Malaria. Journal of Infectious Diseases, 2012, 206, 571-579.	4.0	64
480	Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. American Journal of Tropical Medicine and Hygiene, 2004, 71, 179-86.	1.4	64
481	Severe allergic reactions to oral artesunate: a report of two cases. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 182-183.	1.8	63
482	Pitfalls in Estimating Piperaquine Elimination. Antimicrobial Agents and Chemotherapy, 2005, 49, 5127-5128.	3.2	63
483	Limited Polymorphism in the Dihydropteroate Synthetase Gene (dhps) of Plasmodium vivax Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2005, 49, 4393-4395.	3.2	63
484	A Brief History of Qinghaosu. Trends in Parasitology, 2015, 31, 607-610.	3.3	63
485	Population Genetic Analysis of Plasmodium falciparum Parasites Using a Customized Illumina GoldenGate Genotyping Assay. PLoS ONE, 2011, 6, e20251.	2.5	63
486	Single Low Dose Primaquine (0.25mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects. PLoS ONE, 2016, 11, e0151898.	2.5	63

#	Article	IF	Citations
487	Pharmacokinetics of Three Commercial Antivenoms in Patients Envenomed by the Malayan Pit Viper, Calloselasma Rhodostoma, in Thailand. American Journal of Tropical Medicine and Hygiene, 1990, 42, 260-266.	1.4	63
488	Oral Artesunate in the Treatment of Uncomplicated Hyperparasitemic Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1995, 53, 522-525.	1.4	63
489	Complex Visual Hallucinations in Partial Blindness due to Eye Disease. British Journal of Psychiatry, 1980, 136, 284-286.	2.8	62
490	Quinine disposition kinetics British Journal of Clinical Pharmacology, 1983, 16, 399-403.	2.4	62
491	Effects on growth of single short courses of fluoroquinolones Archives of Disease in Childhood, 1996, 74, 44-46.	1.9	62
492	Risk factors for typhoid fever in the Mekong delta, southern Viet Nam: a case-control study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 19-23.	1.8	62
493	Counterfeit artesunate antimalarials in southeast Asia. Lancet, The, 2003, 362, 169.	13.7	62
494	Predicting the clinical outcome of tetanus: the tetanus severity score. Tropical Medicine and International Health, 2006, 11, 279-287.	2.3	62
495	Population pharmacokinetics of artesunate and amodiaquine in African children. Malaria Journal, 2009, 8, 200.	2.3	62
496	Clinical Research in Resource-Limited Settings: Enhancing Research Capacity and Working Together to Make Trials Less Complicated. PLoS Neglected Tropical Diseases, 2010, 4, e619.	3.0	62
497	Randomized, Double-Blind, Placebo-Controlled Trial of Monthly versus Bimonthly Dihydroartemisinin-Piperaquine Chemoprevention in Adults at High Risk of Malaria. Antimicrobial Agents and Chemotherapy, 2012, 56, 1571-1577.	3.2	62
498	Optimum population-level use of artemisinin combination therapies: a modelling study. The Lancet Global Health, 2015, 3, e758-e766.	6.3	62
499	Microvascular obstruction and endothelial activation are independently associated with the clinical manifestations of severe falciparum malaria in adults: an observational study. BMC Medicine, 2015, 13, 122.	5.5	62
500	Influence of the number and timing of malaria episodes during pregnancy on prematurity and small-for-gestational-age in an area of low transmission. BMC Medicine, 2017, 15, 117.	5.5	62
501	Tumor Necrosis Factor in Septicemic Melioidosis. Journal of Infectious Diseases, 1992, 165, 561-564.	4.0	61
502	Oral fluoroquinolones for maintenance treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 599-601.	1.8	61
503	Arthropod Borne Disease: The Leading Cause of Fever in Pregnancy on the Thai-Burmese Border. PLoS Neglected Tropical Diseases, 2010, 4, e888.	3.0	61
504	Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malaria Journal, 2014, 13, 483.	2.3	61

#	Article	IF	Citations
505	Artesunate versus artemether for the treatment of recrudescent multidrug-resistant falciparum malaria American Journal of Tropical Medicine and Hygiene, 1998, 59, 883-888.	1.4	61
506	Short report: a rapid method for the differentiation of Burkholderia pseudomallei and Burkholderia thailandensis American Journal of Tropical Medicine and Hygiene, 2002, 66, 759-761.	1.4	61
507	Causes of community-acquired bacteremia and patterns of antimicrobial resistance in Vientiane, Laos. American Journal of Tropical Medicine and Hygiene, 2006, 75, 978-85.	1.4	61
508	Intracranial pressure in childhood cerebral malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 362-364.	1.8	60
509	Pseudomonas pseudomallei Liver Abscesses: A Clinical, Laboratory, and Ultrasonographic Study. Clinical Infectious Diseases, 1992, 14, 412-417.	5.8	60
510	Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malaria Journal, 2006, 5, 127.	2.3	60
511	Collagen and mature elastic fibre organisation as a function of depth in the human cornea and limbus. Journal of Structural Biology, 2010, 169, 424-430.	2.8	60
512	Clinically Unapparent Infantile Thiamin Deficiency in Vientiane, Laos. PLoS Neglected Tropical Diseases, 2011, 5, e969.	3.0	60
513	Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. British Journal of Clinical Pharmacology, 2012, 73, 467-477.	2.4	60
514	Infectious Mononucleosis Hepatitis. Seminars in Liver Disease, 1984, 4, 301-306.	3.6	59
515	Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 195-198.	1.8	59
516	A Prospective Study of AIDS-associated Cryptococcal Meningitis in Thailand Treated with High-dose Amphotericin B. Journal of Infection, 2001, 43, 226-233.	3.3	59
517	Baseline Correlation and Comparative Kinetics of Cerebrospinal Fluid Colonyâ€Forming Unit Counts and Antigen Titers in Cryptococcal Meningitis. Journal of Infectious Diseases, 2005, 192, 681-684.	4.0	59
518	Geographical Distribution of Selected and Putatively Neutral SNPs in Southeast Asian Malaria Parasites. Molecular Biology and Evolution, 2005, 22, 2362-2374.	8.9	59
519	Population Pharmacokinetics of Artesunate and Dihydroartemisinin following Intra-Rectal Dosing of Artesunate in Malaria Patients. PLoS Medicine, 2006, 3, e444.	8.4	59
520	The eye in cerebral malaria: what can it teach us?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2009, 103, 661-664.	1.8	59
521	Community engagement on the Thai-Burmese border: rationale, experience and lessons learnt. International Health, 2010, 2, 123-129.	2.0	59
522	Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 5500-5506.	3.2	59

#	Article	IF	CITATIONS
523	Estimation of gestational age from fundal height: a solution for resource-poor settings. Journal of the Royal Society Interface, 2012, 9, 503-510.	3.4	59
524	Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrobial Agents and Chemotherapy, 1994, 38, 511-514.	3.2	58
525	A comparison of the in vivo kinetics of Plasmodium falciparum ring–infected erythrocyte surface antigen–positive and –negative erythrocytes. Blood, 2001, 98, 450-457.	1.4	58
526	Dietary and socio-economic factors associated with beriberi in breastfed Lao infants. Annals of Tropical Paediatrics, 2003, 23, 181-186.	1.0	58
527	The changing pattern of bloodstream infections associated with the rise in HIV prevalence in northeastern Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 678-686.	1.8	58
528	Pharmacokinetics of Oral Doxycycline during Combination Treatment of Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2005, 49, 1622-1625.	3.2	58
529	An open, randomized comparison of artesunate plus mefloquine ⟨i>vs.⟨ i> dihydroartemisinin–piperaquine for the treatment of uncomplicated ⟨i>Plasmodium falciparum⟨ i> malaria in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health, 2006. 11. 1157-1165.	2.3	58
530	Identification of cryptic coinfection with Plasmodium falciparum in patients presenting with vivax malaria American Journal of Tropical Medicine and Hygiene, 2001, 65, 588-592.	1.4	58
531	MEPTAZINOL DIMINISHES THE JARISCH-HERXHEIMER REACTION OF RELAPSING FEVER. Lancet, The, 1983, 321, 835-839.	13.7	57
532	Studies of mefloquine bioavailability and kinetics using a stable isotope technique: a comparison of Thai patients with falciparum malaria and healthy Caucasian volunteers British Journal of Clinical Pharmacology, 1987, 24, 37-42.	2.4	57
533	Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistantPlasmodium falciparum malaria in pregnancy: A preliminary report. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 592-594.	1.8	57
534	Short Communication: An assessment of the use of malaria rapid tests by village health volunteers in rural Laos. Tropical Medicine and International Health, 2004, 9, 325-329.	2.3	57
535	Impact of improved vaccination programme and intensive care facilities on incidence and outcome of tetanus in southern Vietnam, 1993–2002. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 671-677.	1.8	57
536	Rapid Immunofluorescence Microscopy for Diagnosis of Melioidosis. Vaccine Journal, 2005, 12, 555-556.	3.1	57
537	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal, 2007, 6, 119.	2.3	57
538	A liquid chromatographic-tandem mass spectrometric method for determination of artesunate and its metabolite dihydroartemisinin in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 876, 61-68.	2.3	57
539	How antimalarial drug resistance affects post-treatment prophylaxis. Malaria Journal, 2008, 7, 9.	2.3	57
540	Erythrocyte sequestration and anemia in severe falciparum malaria. Analysis of acute changes in venous hematocrit using a simple mathematical model Journal of Clinical Investigation, 1990, 86, 793-800.	8.2	57

#	Article	IF	Citations
541	Single dose pharmacokinetics of proguanil and its metabolites in healthy subjects British Journal of Clinical Pharmacology, 1987, 24, 775-780.	2.4	56
542	In vitro antimicrobial susceptibilities of strains of Yersinia pestis. Antimicrobial Agents and Chemotherapy, 1995, 39, 2153-2154.	3.2	56
543	Lipopolysaccharide from Nonvirulent Ara ⁺ <i>Burkholderia pseudomallei</i> Isolates Is Immunologically Indistinguishable from Lipopolysaccharide from Virulent Ara ^{â^'} Clinical Isolates. Vaccine Journal, 1998, 5, 225-229.	2.6	56
544	A Safe and Effective Consecutive-Infusion Regimen for Rapid Quinine Loading in Severe Falciparum Malaria. Journal of Infectious Diseases, 1990, 161, 1305-1308.	4.0	55
545	Cellular stress and injury responses in the brains of adult Vietnamese patients with fatal Plasmodium falciparum malaria. Neuropathology and Applied Neurobiology, 2001, 27, 421-433.	3.2	55
546	Quinine Pharmacokinetic-Pharmacodynamic Relationships in Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2003, 47, 3458-3463.	3.2	55
547	Plateletâ€Induced Autoagglutination ofPlasmodium falciparum–Infected Red Blood Cells and Disease Severity in Thailand. Journal of Infectious Diseases, 2004, 189, 1052-1055.	4.0	55
548	Serum antibody responses to pneumococcal colonization in the first 2 years of life: results from an SE Asian longitudinal cohort study. Clinical Microbiology and Infection, 2013, 19, E551-E558.	6.0	55
549	Value of Throat Swab in Diagnosis of Melioidosis. Journal of Clinical Microbiology, 2001, 39, 3801-3802.	3.9	54
550	Neuropathological assessment of artemether-treated severe malaria. Lancet, The, 2003, 362, 295-296.	13.7	54
551	Pharmacokinetic Properties ofAntiâ€Influenza Neuraminidase Inhibitors. Journal of Clinical Pharmacology, 2013, 53, 119-139.	2.0	54
552	Transverse depth-dependent changes in corneal collagen lamellar orientation and distribution. Journal of the Royal Society Interface, 2015, 12, 20140717.	3.4	54
553	Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malaria Journal, 2016, 15, 181.	2.3	54
554	Microvesicles from malaria-infected red blood cells activate natural killer cells via MDA5 pathway. PLoS Pathogens, 2018, 14, e1007298.	4.7	54
555	Cardiovascular abnormalities in osteogenesis imperfecta. American Heart Journal, 1983, 106, 1416-1420.	2.7	53
556	Measures of Capillary Permeability in Acute Falciparum Malaria: Relation to Severity of Infection and Treatment. Clinical Infectious Diseases, 1992, 15, 256-266.	5.8	53
557	Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 321-323.	1.8	53
558	Electrocardiographic monitoring in severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 266-269.	1.8	53

#	Article	IF	CITATIONS
559	The business and the politics of decolonization: the British experience in the twentieth century. Economic History Review, 2000, 53, 544-564.	0.9	53
560	A new approach to evaluate regression models during validation of bioanalytical assays. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 219-227.	2.8	53
561	A review of mixed malaria species infections in anopheline mosquitoes. Malaria Journal, 2011, 10, 253.	2.3	53
562	Community engagement and the social context of targeted malaria treatment: a qualitative study in Kayin (Karen) State, Myanmar. Malaria Journal, 2017, 16, 75.	2.3	53
563	Splenic Fc Receptor Function in Host Defense and Anemia in Acute Plasmodium falciparum Malaria. Journal of Infectious Diseases, 1990, 161, 555-561.	4.0	52
564	Single dose pharmacokinetics of proguanil and its metabolites in pregnancy. European Journal of Clinical Pharmacology, 1993, 44, 247-251.	1.9	52
565	Low Effective Dispersal of Asexual Genotypes in Heterogeneous Landscapes by the Endemic Pathogen Penicillium marneffei. PLoS Pathogens, 2005, 1, e20.	4.7	52
566	Limited Diagnostic Capacities of Two Commercial Assays for the Detection of Leptospira Immunoglobulin M Antibodies in Laos. Vaccine Journal, 2006, 13, 1166-1169.	3.1	52
567	Major pitfalls in the measurement of artemisinin derivatives in plasma in clinical studies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2008, 876, 54-60.	2.3	52
568	Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial. Malaria Journal, 2010, 9, 105.	2.3	52
569	Comparison of the Cumulative Efficacy and Safety of Chloroquine, Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2018, 67, 1543-1549.	5.8	52
570	Quinine induces reversible highâ€ŧone hearing loss British Journal of Clinical Pharmacology, 1990, 29, 780-782.	2.4	51
571	Susceptibility of Pseudomonas pseudomallei to some newer \hat{l}^2 -lactam antibiotics and antibiotic combinations using time-kill studies. Journal of Antimicrobial Chemotherapy, 1994, 33, 145-149.	3.0	51
572	Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. Malaria Journal, 2013, 12, 289.	2.3	51
573	Does antimalarial mass drug administration increase or decrease the risk of resistance?. Lancet Infectious Diseases, The, 2017, 17, e15-e20.	9.1	51
574	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
575	Rapid Identification of Burkholderia pseudomallei by Latex Agglutination Based on an Exopolysaccharide-Specific Monoclonal Antibody. Journal of Clinical Microbiology, 1999, 37, 225-228.	3.9	51
576	LIPOPOLYSACCHARIDE HETEROGENEITY AMONG BURKHOLDERIA PSEUDOMALLEI FROM DIFFERENT GEOGRAPHIC AND CLINICAL ORIGINS. American Journal of Tropical Medicine and Hygiene, 2006, 74, 348-352.	1.4	51

#	Article	IF	CITATIONS
577	Ex-vivo short-term culture and developmental assessment of Plasmodium vivax. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 677-680.	1.8	50
578	An open label randomized comparison of mefloquine?artesunate as separate tablets vs. a new co-formulated combination for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. Tropical Medicine and International Health, 2006, 11, 1653-1660.	2.3	50
579	Likely Health Outcomes for Untreated Acute Febrile Illness in the Tropics in Decision and Economic Models; A Delphi Survey. PLoS ONE, 2011, 6, e17439.	2.5	50
580	Randomized Controlled Trial of Levamisole Hydrochloride as Adjunctive Therapy in Severe Falciparum Malaria With High Parasitemia. Journal of Infectious Diseases, 2014, 209, 120-129.	4.0	50
581	Pregnancy Outcome in Relation to Treatment of Murine Typhus and Scrub Typhus Infection: A Fever Cohort and a Case Series Analysis. PLoS Neglected Tropical Diseases, 2014, 8, e3327.	3.0	50
582	Contribution of Asymptomatic Plasmodium Infections to the Transmission of Malaria in Kayin State, Myanmar. Journal of Infectious Diseases, 2019, 219, 1499-1509.	4.0	50
583	Pharmacokinetics of Mefloquine Combined with Artesunate in Children with Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 1999, 43, 341-346.	3.2	50
584	Molecular Typing of Multiple-Antibiotic-Resistant <i>Salmonella enterica</i> Serovar Typhi from Vietnam: Application to Acute and Relapse Cases of Typhoid Fever. Journal of Clinical Microbiology, 1999, 37, 2466-2472.	3.9	50
585	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50
586	Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treating falciparum malaria. Bulletin of the World Health Organization, 2006, 84, 956-964.	3.3	50
587	RAPID DIAGNOSIS OF SCRUB TYPHUS IN RURAL THAILAND USING POLYMERASE CHAIN REACTION. American Journal of Tropical Medicine and Hygiene, 2006, 75, 1099-1102.	1.4	50
588	Interactions in vitro between agents used to treat melioidosis. Journal of Antimicrobial Chemotherapy, 1989, 24, 311-316.	3.0	49
589	Biochemical Evidence of Muscle Injury in African Children with Severe Malaria. Journal of Infectious Diseases, 1989, 159, 139-142.	4.0	49
590	Glucose turnover in severe falciparum malaria. Metabolism: Clinical and Experimental, 1993, 42, 334-340.	3.4	49
591	Role of quinine in the high mortality of intramuscular injection tetanus. Lancet, The, 1994, 344, 786-787.	13.7	49
592	A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor) Tj ETQq0 0 0 rgB 693-696.	「/Overloch 3.2	₹ 10 Tf 50 1 49
593	Serological and blood culture investigations of Nepalese fever patients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2007, 101, 686-690.	1.8	49
594	Evaluation of a PfHRP2 and a pLDH-based Rapid Diagnostic Test for the Diagnosis of Severe Malaria in 2 Populations of African Children. Clinical Infectious Diseases, 2011, 52, 1100-1107.	5.8	49

#	Article	IF	CITATIONS
595	The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies. PLoS Medicine, 2016, 13, e1001984.	8.4	49
596	Chloroquine Versus Dihydroartemisinin-Piperaquine With Standard High-dose Primaquine Given Either for 7 Days or 14 Days in Plasmodium vivax Malaria. Clinical Infectious Diseases, 2019, 68, 1311-1319.	5.8	49
597	Acute Encephalopathy Associated with Influenza A Infection in Adults. Emerging Infectious Diseases, 2010, 16, 139-142.	4.3	49
598	Contribution of humoral immunity to the therapeutic response in falciparum malaria American Journal of Tropical Medicine and Hygiene, 2001, 65, 918-923.	1.4	49
599	Ribotype differences between clinical and environmental isolates of Burkholderia pseudomallei. Journal of Medical Microbiology, 1997, 46, 565-570.	1.8	48
600	Effect of High-Dose or Split-Dose Artesunate on Parasite Clearance in Artemisinin-Resistant Falciparum Malaria. Clinical Infectious Diseases, 2013, 56, e48-e58.	5.8	48
601	Falsified medicines in Africa: all talk, no action. The Lancet Global Health, 2014, 2, e509-e510.	6.3	48
602	A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages. Clinical Infectious Diseases, 2018, 67, 817-826.	5.8	48
603	IN VITRO EFFICACY OF ANTIMALARIAL DRUGS AGAINST PLASMODIUM VIVAX ON THE WESTERN BORDER OF THAILAND. American Journal of Tropical Medicine and Hygiene, 2004, 70, 395-397.	1.4	48
604	A CASE-CONTROL AUDITORY EVALUATION OF PATIENTS TREATED WITH ARTEMETHER-LUMEFANTRINE. American Journal of Tropical Medicine and Hygiene, 2006, 74, 211-214.	1.4	48
605	Pharmacokinetics of intravenous amodiaquine British Journal of Clinical Pharmacology, 1987, 23, 127-135.	2.4	47
606	Adverse Effect of Rifampin on Quinine Efficacy in Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2003, 47, 1509-1513.	3.2	47
607	Development and validation of a bioanalytical method using automated solid-phase extraction and LC-UV for the simultaneous determination of lumefantrine and its desbutyl metabolite in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 1081-1088.	2.8	47
608	Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis. Antimicrobial Agents and Chemotherapy, 2009, 53, 4193-4199.	3.2	47
609	Magnetic resonance imaging of the brain in adults with severe falciparum malaria. Malaria Journal, 2014, 13, 177.	2.3	47
610	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
611	An inventory of supranational antimicrobial resistance surveillance networks involving low- and middle-income countries since 2000. Journal of Antimicrobial Chemotherapy, 2018, 73, 1737-1749.	3.0	47
612	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47

#	Article	IF	Citations
613	Treatment-seeking behaviour for febrile illnesses and its implications for malaria control and elimination in Savannakhet Province, Lao PDR (Laos): a mixed method study. BMC Health Services Research, 2019, 19, 252.	2.2	47
614	An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 584-585.	1.8	46
615	Not much progress in treatment of cerebral malaria. Lancet, The, 1998, 352, 594-595.	13.7	46
616	Melioidosis and Pandora's Box in the Lao People's Democratic Republic. Clinical Infectious Diseases, 2001, 32, 653-654.	5.8	46
617	Differential expression of interferon- \hat{l}^3 and interferon- \hat{l}^3 -inducing cytokines in Thai patients with scrub typhus or leptospirosis. Clinical Immunology, 2004, 113, 140-144.	3.2	46
618	Coma in fatal adult human malaria is not caused by cerebral oedema. Malaria Journal, 2011, 10, 267.	2.3	46
619	Past and new challenges for malaria control and elimination: the role of operational research for innovation in designing interventions. Malaria Journal, 2015, 14, 279.	2.3	46
620	Genomic structure and diversity of Plasmodium falciparum in Southeast Asia reveal recent parasite migration patterns. Nature Communications, 2019, 10, 2665.	12.8	46
621	Effects of Different Antimalarial Drugs on Gametocyte Carriage in P. Vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2008, 79, 378-384.	1.4	46
622	World Antimalarial Resistance Network (WARN) IV: Clinical pharmacology. Malaria Journal, 2007, 6, 122.	2.3	45
623	Pharmacokinetics of Amodiaquine and Desethylamodiaquine in Pregnant and Postpartum Women with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 4338-4342.	3.2	45
624	Evaluating Clinical Trial Designs for Investigational Treatments of Ebola Virus Disease. PLoS Medicine, 2015, 12, e1001815.	8.4	45
625	Asymptomatic Plasmodium infections in 18 villages of southern Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2016, 15, 296.	2.3	45
626	Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria. PLoS Neglected Tropical Diseases, 2018, 12, e0006440.	3.0	45
627	Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 913-923.	9.1	45
628	Community engagement, social context and coverage of mass anti-malarial administration: Comparative findings from multi-site research in the Greater Mekong sub-Region. PLoS ONE, 2019, 14, e0214280.	2.5	45
629	Activation of the coagulation cascade in falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1989, 83, 762-766.	1.8	44
630	Dichloroacetate for lactic acidosis in severe malaria: A pharmacokinetic and pharmacodynamic assessment. Metabolism: Clinical and Experimental, 1994, 43, 974-981.	3.4	44

#	Article	IF	Citations
631	Population Pharmacokinetic Assessment of a New Regimen of Mefloquine Used in Combination Treatment of Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2006, 50, 2281-2285.	3.2	44
632	Parasitological efficacy of antimalarials in the treatment and prevention of falciparum malaria in pregnancy 1998 to 2009: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 123-135.	2.3	44
633	Cost-effectiveness of parenteral artesunate for treating children with severe malaria in sub-Saharan Africa. Bulletin of the World Health Organization, 2011, 89, 504-512.	3.3	44
634	Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy. Antimicrobial Agents and Chemotherapy, 2012, 56, 5764-5773.	3.2	44
635	Motivations and perceptions of community advisory boards in the ethics of medical research: the case of the Thai-Myanmar border. BMC Medical Ethics, 2014, 15, 12.	2.4	44
636	Artemetherâ€lumefantrine coâ€administration with antiretrovirals: population pharmacokinetics and dosing implications. British Journal of Clinical Pharmacology, 2015, 79, 636-649.	2.4	44
637	Acetaminophen as a Renoprotective Adjunctive Treatment in Patients With Severe and Moderately Severe Falciparum Malaria: A Randomized, Controlled, Open-Label Trial. Clinical Infectious Diseases, 2018, 67, 991-999.	5.8	44
638	Epidemic Typhoid in Vietnam: Molecular Typing of Multiple-Antibiotic-Resistant Salmonella enterica Serotype Typhi from Four Outbreaks. Journal of Clinical Microbiology, 2000, 38, 895-897.	3.9	44
639	Quinine pharmacokinetics in cerebral malaria: predicted plasma concentrations after rapid intravenous loading using a two-compartment model. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 542-547.	1.8	43
640	Interleukin-8 and Plasmodium falciparum malaria in Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 54-55.	1.8	43
641	Survival of Burkholderia pseudomallei in the absence of nutrients. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 491.	1.8	43
642	High throughput assay for the determination of lumefantrine in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 822, 330-333.	2.3	43
643	Molecular Correlates of High-Level Antifolate Resistance in Rwandan Children with <i>Plasmodium falciparum (i) Malaria. Antimicrobial Agents and Chemotherapy, 2010, 54, 477-483.</i>	3.2	43
644	Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. Journal of Infectious Diseases, 2013, 208, 801-812.	4.0	43
645	Parasite clearance rates in Upper Myanmar indicate a distinctive artemisinin resistance phenotype: a therapeutic efficacy study. Malaria Journal, 2016, 15, 185.	2.3	43
646	Mediation of the effect of malaria in pregnancy on stillbirth and neonatal death in an area of low transmission: observational data analysis. BMC Medicine, 2017, 15, 98.	5.5	43
647	Neonatal Intensive Care in a Karen Refugee Camp: A 4 Year Descriptive Study. PLoS ONE, 2013, 8, e72721.	2.5	43
648	Specimens and culture media for the laboratory diagnosis of typhoid fever. Journal of Infection in Developing Countries, 2008, 2, 469-74.	1.2	43

#	Article	IF	Citations
649	CLINICAL TRIAL OF ORAL ARTESUNATE WITH OR WITHOUT HIGH-DOSE PRIMAQUINE FOR THE TREATMENT OF VIVAX MALARIA IN THAILAND. American Journal of Tropical Medicine and Hygiene, 2003, 69, 14-18.	1.4	43
650	Convulsions in childhood malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 426-428.	1.8	42
651	A simple method for assessing quinine pre-treatment in acute malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 665-667.	1.8	42
652	A double-blind randomized therapeutic trial of insect repellents for the prevention of malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 137-138.	1.8	42
653	Comparison of Oral Artesunate and Dihydroartemisinin Antimalarial Bioavailabilities in Acute Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2002, 46, 1125-1127.	3.2	42
654	Detection of Burkholderia pseudomallei in Soil within the Lao People's Democratic Republic. Journal of Clinical Microbiology, 2005, 43, 923-924.	3.9	42
655	Intrahost Selection of Plasmodium falciparum pfmdr 1 Alleles after Antimalarial Treatment on the Northwestern Border of Thailand. Journal of Infectious Diseases, 2007, 195, 134-141.	4.0	42
656	The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malaria Journal, 2008, 7, 149.	2.3	42
657	What Is the Optimal Therapy for Patients with H5N1 Influenza?. PLoS Medicine, 2009, 6, e1000091.	8.4	42
658	Randomized controlled trial of artesunate or artemether in Vietnamese adults with severe falciparum malaria. Malaria Journal, 2010, 9, 97.	2.3	42
659	Open-Label Crossover Study of Primaquine and Dihydroartemisinin-Piperaquine Pharmacokinetics in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 7340-7346.	3.2	42
660	Empirical Cephalosporin Treatment of Melioidosis. Clinical Infectious Diseases, 1999, 28, 1328-1328.	5.8	41
661	The Beginnings of Crony Capitalism: Business, Politics and Economic Development in Malaysia, c. 1955–70. Modern Asian Studies, 2004, 38, 389-417.	0.4	41
662	Surviving Sukarno: British Business in Post-Colonial Indonesia, 1950–1967. Modern Asian Studies, 2012, 46, 1277-1315.	0.4	41
663	Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda. Antimicrobial Agents and Chemotherapy, 2013, 57, 5096-5103.	3.2	41
664	Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated <i>Plasmodium falciparum</i> Malaria in Uganda. CPT: Pharmacometrics and Systems Pharmacology, 2013, 2, 1-10.	2.5	41
665	A brief measure of adolescent perceptions of school climate School Psychology Quarterly, 2014, 29, 349-359.	2.0	41
666	Pharmacokinetic Interactions between Primaquine and Pyronaridine-Artesunate in Healthy Adult Thai Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 505-513.	3.2	41

#	Article	IF	CITATIONS
667	K13 Propeller Mutations in Plasmodium falciparum Populations in Regions of Malaria Endemicity in Vietnam from 2009 to 2016. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	41
668	The origins of malaria artemisinin resistance defined by a genetic and transcriptomic background. Nature Communications, 2018, 9, 5158.	12.8	41
669	Why do people participate in mass anti-malarial administration? Findings from a qualitative study in Nong District, Savannakhet Province, Lao PDR (Laos). Malaria Journal, 2018, 17, 15.	2.3	41
670	Genotyping of Plasmodium vivax Reveals Both Short and Long Latency Relapse Patterns in Kolkata. PLoS ONE, 2012, 7, e39645.	2.5	41
671	DISEASE SEVERITY AND OUTCOME OF MELIOIDOSIS IN HIV COINFECTED INDIVIDUALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 1165-1166.	1.4	41
672	Electrocardiographic Safety Evaluation of Dihydroartemisinin–Piperaquine in the Treatment of Uncomplicated falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-450.	1.4	41
673	Effects of Malaria Heme Products on Red Blood Cell Deformability. American Journal of Tropical Medicine and Hygiene, 2007, 77, 617-622.	1.4	41
674	Artesunate and mefloquine in the treatment of uncomplicated multidrug-resistant hyperparasitaemic falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 207-211.	1.8	40
675	A genome-wide search for linkage to asthma phenotypes in the genetics of asthma international network families: evidence for a major susceptibility locus on chromosome 2p. European Journal of Human Genetics, 2006, 14, 307-316.	2.8	40
676	A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu \hat{A}^{\otimes} . Journal of Pharmaceutical and Biomedical Analysis, 2006, 42, 430-433.	2.8	40
677	Levamisole Inhibits Sequestration of Infected Red Blood Cells in Patients with Falciparum Malaria. Journal of Infectious Diseases, 2007, 196, 460-466.	4.0	40
678	Chloroquine pharmacokinetics in pregnant and nonpregnant women with vivax malaria. European Journal of Clinical Pharmacology, 2008, 64, 987-992.	1.9	40
679	ORIGINAL ARTICLE: Probability of emergence of antimalarial resistance in different stages of the parasite life cycle. Evolutionary Applications, 2009, 2, 52-61.	3.1	40
680	Laboratory Detection of Artemisinin-Resistant Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2014, 58, 3157-3161.	3.2	40
681	Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia. Malaria Journal, 2017, 16, 56.	2.3	40
682	Malaria elimination in remote communities requires integration of malaria control activities into general health care: an observational study and interrupted time series analysis in Myanmar. BMC Medicine, 2018, 16, 183.	5.5	40
683	Short Report: Rosette Formation in Plasmodium ovale Infection. American Journal of Tropical Medicine and Hygiene, 1996, 55, 560-561.	1.4	40
684	Praziquantel Pharmacokinetics and Side Effects in Schistosoma japonicum-Infected Patients with Liver Disease. Journal of Infectious Diseases, 1988, 157, 530-535.	4.0	39

#	Article	IF	Citations
685	Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas psemdomallei. Journal of Antimicrobial Chemotherapy, 1991, 28, 321-324.	3.0	39
686	Interactions among primaquine, malaria infection and other antimalarials in Thai subjects British Journal of Clinical Pharmacology, 1993, 35, 193-198.	2.4	39
687	Melioidosis in Southern Vietnam: Clinical Surveillance and Environmental Sampling. Clinical Infectious Diseases, 1999, 29, 1323-1326.	5.8	39
688	Skeletal Muscle Involvement in Falciparum Malaria: Biochemical and Ultrastructural Study. Clinical Infectious Diseases, 1999, 29, 831-835.	5.8	39
689	Haematinic treatment of anaemia increases the risk of Plasmodium vivax malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 273-276.	1.8	39
690	Use of Paired Serum Samples for Serodiagnosis of Typhoid Fever. Journal of Clinical Microbiology, 2005, 43, 4889-4890.	3.9	39
691	Rapid Degradation of Oseltamivir Phosphate in Clinical Samples by Plasma Esterases. Antimicrobial Agents and Chemotherapy, 2006, 50, 3197-3199.	3.2	39
692	The infective causes of hepatitis and jaundice amongst hospitalised patients in Vientiane, Laos. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2010, 104, 475-483.	1.8	39
693	A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malaria Journal, 2012, 11, 398.	2.3	39
694	Elimination of Plasmodium falciparum in an area of multi-drug resistance. Malaria Journal, 2015, 14, 319.	2.3	39
695	The prevention and treatment of Plasmodium vivax malaria. PLoS Medicine, 2021, 18, e1003561.	8.4	39
696	Red cell deformability, splenic function and anaemia in thalassaemia. British Journal of Haematology, 1999, 105, 505-508.	2.5	38
697	Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2000, 94, 323-326.	1.8	38
698	Characterization of Human Urinary Metabolites of the Antimalarial Piperaquine. Drug Metabolism and Disposition, 2006, 34, 2011-2019.	3.3	38
699	Timing of Enteral Feeding in Cerebral Malaria in Resource-Poor Settings: A Randomized Trial. PLoS ONE, 2011, 6, e27273.	2.5	38
700	Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malaria Journal, 2012, 11, 293.	2.3	38
701	Entomological determinants of insecticide-treated bed net effectiveness in Western Myanmar. Malaria Journal, 2013, 12, 364.	2.3	38
702	Short report: hepatitis b infection and severe Plasmodium falciparum malaria in Vietnamese adults American Journal of Tropical Medicine and Hygiene, 2002, 66, 140-142.	1.4	38

#	Article	IF	CITATIONS
703	Modelling primaquine-induced haemolysis in G6PD deficiency. ELife, 2017, 6, .	6.0	38
704	Two patients with falciparum malaria and poor in vivo responses to artesunate. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 668-669.	1.8	37
705	Assessment of the neurotoxicity of oral dihydroartemisinin in mice. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2002, 96, 99-101.	1.8	37
706	Oxidative stress and rheology in severe malaria. Redox Report, 2003, 8, 292-294.	4.5	37
707	Artemether Bioavailability after Oral or Intramuscular Administration in Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2003, 47, 3795-3798.	3.2	37
708	Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. International Journal of Infectious Diseases, 2006, 10, 25-31.	3.3	37
709	The pharmacokinetics of intravenous artesunate in adults with severe falciparum malaria. European Journal of Clinical Pharmacology, 2006, 62, 1003-1009.	1.9	37
710	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
711	Antimalarial mass drug administration: ethical considerations. International Health, 2016, 8, 235-238.	2.0	37
712	Relationships among Pseudomonas pseudomallei isolates from patients with recurrent melioidosis. Journal of Clinical Microbiology, 1993, 31, 1592-1596.	3.9	37
713	ACTIVATION OF CYTOTOXIC LYMPHOCYTES IN PATIENTS WITH SCRUB TYPHUS. American Journal of Tropical Medicine and Hygiene, 2005, 72, 465-467.	1.4	37
714	Prognostic Value of Electrocardiographic Monitoring of Patients with Severe Diphtheria. Clinical Infectious Diseases, 1995, 20, 1259-1265.	5.8	36
715	Plasmodium falciparum: sensitivity in vivo to chloroquine, pyrimethamine/sulfadoxine and mefloquine in western Myanmar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 468-472.	1.8	36
716	Role and Significance of Quantitative Urine Cultures in Diagnosis of Melioidosis. Journal of Clinical Microbiology, 2005, 43, 2274-2276.	3.9	36
717	Are Extensive T Cell Epitope Polymorphisms in thePlasmodium falciparumCircumsporozoite Antigen, a Leading Sporozoite Vaccine Candidate, Selected by Immune Pressure?. Journal of Immunology, 2005, 175, 3935-3939.	0.8	36
718	Susceptibility of communityâ€acquired pathogens to antibiotics in Africa and Asia in neonates – an alarmingly short review. Tropical Medicine and International Health, 2011, 16, 145-151.	2.3	36
719	Population Pharmacokinetics of Intramuscular Artesunate in African Children With Severe Malaria: Implications for a Practical Dosing Regimen. Clinical Pharmacology and Therapeutics, 2013, 93, 443-450.	4.7	36
720	High Rates of Pneumonia in Children under Two Years of Age in a South East Asian Refugee Population. PLoS ONE, 2013, 8, e54026.	2.5	36

#	Article	IF	Citations
721	The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis. BMC Medicine, 2015, 13, 97.	5.5	36
722	Defining the In Vivo Phenotype of Artemisinin-Resistant Falciparum Malaria: A Modelling Approach. PLoS Medicine, 2015, 12, e1001823.	8.4	36
723	Genomic Characterization of Recrudescent <i>Plasmodium malariae</i> Artemether/Lumefantrine. Emerging Infectious Diseases, 2017, 23, 1300-1307.	4.3	36
724	Advances and roadblocks in the treatment of malaria. British Journal of Clinical Pharmacology, 2022, 88, 374-382.	2.4	36
725	Characteristics of Plasmodium vivax-infected erythrocyte rosettes American Journal of Tropical Medicine and Hygiene, 1998, 59, 73-76.	1.4	36
726	A quantitative ultrastructural study of the liver and the spleen in fatal falciparum malaria. Southeast Asian Journal of Tropical Medicine and Public Health, 2005, 36, 1359-70.	1.0	36
727	Antibodyâ€dependent red cell removal during <i>P. falciparum</i> malaria: the clearance of red cells sensitized with an IgG antiâ€Ð. British Journal of Haematology, 1989, 73, 396-402.	2.5	35
728	Glucose Metabolism In Quinineâ€Treated Patients With Uncomplicated Falciparum Malaria. Clinical Endocrinology, 1990, 33, 739-749.	2.4	35
729	The pharmacokinetic properties of intramuscular quinine in Gambian children with severe falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 488-491.	1.8	35
730	Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment. Antimicrobial Agents and Chemotherapy, 1995, 39, 2356-2358.	3.2	35
731	Pulmonary oedema in vivax malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 421-422.	1.8	35
732	Spatio-temporal patterns of malaria infection in Bhutan: a country embarking on malaria elimination. Malaria Journal, 2011, 10, 89.	2.3	35
733	Randomized Comparison of the Efficacies and Tolerabilities of Three Artemisinin-Based Combination Treatments for Children with Acute Plasmodium falciparum Malaria in the Democratic Republic of the Congo. Antimicrobial Agents and Chemotherapy, 2014, 58, 5528-5536.	3.2	35
734	Plasma Concentration of Parasite DNA as a Measure of Disease Severity in Falciparum Malaria. Journal of Infectious Diseases, 2015, 211, 1128-1133.	4.0	35
735	Identifying the Components of Acidosis in Patients With Severe Plasmodium falciparum Malaria Using Metabolomics. Journal of Infectious Diseases, 2019, 219, 1766-1776.	4.0	35
736	A trade off between catalytic activity and protein stability determines the clinical manifestations of glucose-6-phosphate dehydrogenase (G6PD) deficiency. International Journal of Biological Macromolecules, 2017, 104, 145-156.	7.5	35
737	Amoxycillin-clavulanic acid treatment of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 672-675.	1.8	34
738	Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. British Journal of Clinical Pharmacology, 1993, 36, 585-591.	2.4	34

#	Article	IF	CITATIONS
739	Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Antimicrobial Agents and Chemotherapy, 1996, 40, 2167-2172.	3.2	34
740	A Prospective Clinical and Bacteriologic Study of Inguinal Buboes in Thai Men. Clinical Infectious Diseases, 1996, 22, 233-239.	5.8	34
741	Therapeutic responses to antibacterial drugs in vivax malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 524-528.	1.8	34
742	<i>Ex Vivo</i> Susceptibility of Plasmodium falciparum to Antimalarial Drugs in Western, Northern, and Eastern Cambodia, 2011-2012: Association with Molecular Markers. Antimicrobial Agents and Chemotherapy, 2013, 57, 5277-5283.	3.2	34
743	A Randomized Comparison of Dihydroartemisinin-Piperaquine and Artesunate-Amodiaquine Combined With Primaquine for Radical Treatment of Vivax Malaria in Sumatera, Indonesia. Journal of Infectious Diseases, 2013, 208, 1906-1913.	4.0	34
744	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
745	A systematic review and an individual patient data meta-analysis of ivermectin use in children weighing less than fifteen kilograms: Is it time to reconsider the current contraindication?. PLoS Neglected Tropical Diseases, 2021, 15, e0009144.	3.0	34
746	New Medicines for Tropical Diseases in Pregnancy: Catch-22. PLoS Medicine, 2008, 5, e133.	8.4	34
747	Mefloquine pharmacokinetics and resistance in children with acute falciparum malaria British Journal of Clinical Pharmacology, 1991, 31, 556-559.	2.4	33
748	Immune Cell Activation in Melioidosis: Increased Serum Levels of Interferon-Â and Soluble Interleukin-2 Receptors without Change in Soluble CD8 Protein. Journal of Infectious Diseases, 1991, 163, 1145-1148.	4.0	33
749	A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria. British Journal of Clinical Pharmacology, 2001, 52, 655-661.	2.4	33
750	Chloroquine versus Sulfadoxine-Pyrimethamine for Treatment of Plasmodium falciparum Malaria in Savannakhet Province, Lao People's Democratic Republic: An Assessment of National Antimalarial Drug Recommendations. Clinical Infectious Diseases, 2003, 37, 1021-1028.	5.8	33
751	Clinical Features and Predictors of Diphtheritic Cardiomyopathy in Vietnamese Children. Clinical Infectious Diseases, 2004, 39, 1591-1598.	5.8	33
752	Thiamin deficiency and uncomplicated falciparum malaria in Laos. Tropical Medicine and International Health, 2007, 12, 363-369.	2.3	33
753	Development and validation of a high-throughput zwitterionic hydrophilic interaction liquid chromatography solid-phase extraction–liquid chromatography–tandem mass spectrometry method for determination of the anti-influenza drug peramivir in plasma. Journal of Chromatography A, 2008, 1215. 145-151.	3.7	33
754	Erythrocyte Transketolase Activity, Markers of Cardiac Dysfunction and the Diagnosis of Infantile Beriberi. PLoS Neglected Tropical Diseases, 2011, 5, e971.	3.0	33
755	Liquid chromatographic–mass spectrometric method for simultaneous determination of small organic acids potentially contributing to acidosis in severe malaria. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 941, 116-122.	2.3	33
756	Rapid Isolation and Susceptibility Testing of Leptospira spp. Using a New Solid Medium, LVW Agar. Antimicrobial Agents and Chemotherapy, 2013, 57, 297-302.	3.2	33

#	Article	IF	Citations
757	The diminishing returns of atovaquone-proguanil for elimination of Plasmodium falciparum malaria: modelling mass drug administration and treatment. Malaria Journal, 2014, 13, 380.	2.3	33
758	Factors associated with population coverage of targeted malaria elimination (TME) in southern Savannakhet Province, Lao PDR. Malaria Journal, 2017, 16, 424.	2.3	33
7 59	Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes. PLoS ONE, 2017, 12, e0172718.	2.5	33
760	Defining and Defeating the Intolerable Burden of Malaria III. Progress and Perspectives. American Journal of Tropical Medicine and Hygiene, 2007, 77, vi-xi.	1.4	33
761	Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response. Communications Biology, 2022, 5, 274.	4.4	33
762	Can amodiaquine be resurrected?. Lancet, The, 1996, 348, 1184-1185.	13.7	32
763	Antigenic Differences between Clinical and Environmental Isolates of <i>Burkholderia pseudomallei</i> /i>. Microbiology and Immunology, 1998, 42, 731-737.	1.4	32
764	Editorial: Antimalarial drug resistance and mortality in falciparum malaria. Tropical Medicine and International Health, 1999, 4, 469-470.	2.3	32
765	Nasal Carriage in Vietnamese Children of Streptococcus pneumoniae Resistant to Multiple Antimicrobial Agents. Antimicrobial Agents and Chemotherapy, 2000, 44, 484-488.	3.2	32
766	Development and Evaluation of Rapid Urinary Antigen Detection Tests for Diagnosis of Penicilliosis Marneffei. Journal of Clinical Microbiology, 2002, 40, 3179-3183.	3.9	32
767	Validation and application of a liquid chromatographic–mass spectrometric method for determination of artesunate in pharmaceutical samples. Journal of Pharmaceutical and Biomedical Analysis, 2007, 45, 149-153.	2.8	32
768	A Comparison of Two Short-Course Primaquine Regimens for the Treatment and Radical Cure of Plasmodium vivax Malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 2010, 82, 542-547.	1.4	32
769	Quantification of dihydroartemisinin, artesunate and artemisinin in human blood: overcoming the technical challenge of protecting the peroxide bridge. Bioanalysis, 2011, 3, 1613-1624.	1.5	32
770	Diagnosis, Clinical Presentation, and In-Hospital Mortality of Severe Malaria in HIV-Coinfected Children and Adults in Mozambique. Clinical Infectious Diseases, 2012, 55, 1144-1153.	5.8	32
771	Sequence variation does not confound the measurement of plasma PfHRP2 concentration in African children presenting with severe malaria. Malaria Journal, 2012, 11, 276.	2.3	32
772	A clinicopathological correlation of the expression of the angiopoietin-Tie-2 receptor pathway in the brain of adults with Plasmodium falciparum malaria. Malaria Journal, 2013, 12, 50.	2.3	32
773	Can new treatment developments combat resistance in malaria?. Expert Opinion on Pharmacotherapy, 2016, 17, 1303-1307.	1.8	32
774	Post-treatment haemolysis in African children with hyperparasitaemic falciparum malaria; a randomized comparison of artesunate and quinine. BMC Infectious Diseases, 2017, 17, 575.	2.9	32

#	Article	IF	Citations
775	Global access to quality-assured medical products: the Oxford Statement and call to action. The Lancet Global Health, 2019, 7, e1609-e1611.	6.3	32
776	Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 9, 16-22.	3.4	32
777	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
778	Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-50.	1.4	32
779	Plasmodium yoelii: Blood oxygen and brain function in the infected mouse. Experimental Parasitology, 1983, 56, 391-396.	1.2	31
780	INTRAVENOUS AMODIAQUINE AND ORAL AMODIAQUINE/ERYTHROMYCIN IN THE TREATMENT OF CHLOROQUINE-RESISTANT FALCIPARUM MALARIA. Lancet, The, 1985, 326, 805-808.	13.7	31
781	Selective broths for the isolation of Pseudomonas pseudomallei from clinical samples. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 124.	1.8	31
782	Short courses of ofloxacin for the treatment of enteric fever. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 347-349.	1.8	31
783	Cerebrospinal fluid levels of markers of brain parenchymal damage in Vietnamese adults with severe malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 610-617.	1.8	31
784	A Phase III, Randomized, Non-Inferiority Trial to Assess the Efficacy and Safety of Dihydroartemisinin-Piperaquine in Comparison with Artesunate-Mefloquine in Patients with Uncomplicated Plasmodium falciparum Malaria in Southern Laos. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1221-1229.	1.4	31
785	A sensor array for the discrimination of polycyclic aromatic hydrocarbons using conjugated polymers and the inner filter effect. Chemical Science, 2019, 10, 10247-10255.	7.4	31
786	Mefloquine for multidrug-resistant malaria. Lancet, The, 1991, 338, 1268.	13.7	30
787	A comparison of artesunate alone with combined artesunate and quinine in the parenteral treatment of acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 519-523.	1.8	30
788	The Management of Severe Falciparum Malaria. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 673-674.	5.6	30
789	High throughput assay for the determination of piperaquine in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2005, 39, 601-605.	2.8	30
790	Prospective evaluation of a rapid immunochromogenic cassette test for the diagnosis of melioidosis in northeast Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 64-67.	1.8	30
791	Quantification of artemisinin in human plasma using liquid chromatography coupled to tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 768-773.	2.8	30
792	Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria. European Journal of Clinical Pharmacology, 2010, 66, 705-712.	1.9	30

#	Article	lF	CITATIONS
793	The fluid management of adults with severe malaria. Critical Care, 2014, 18, 642.	5.8	30
794	Safety, Pharmacokinetics, and Mosquitoâ€Lethal Effects of Ivermectin in Combination With Dihydroartemisininâ€Piperaquine and Primaquine in Healthy Adult Thai Subjects. Clinical Pharmacology and Therapeutics, 2020, 107, 1221-1230.	4.7	30
795	Characterization of "Yaa Chud―Medicine on the Thailand–Myanmar Border: Selecting for Drug-resistant Malaria and Threatening Public Health. American Journal of Tropical Medicine and Hygiene, 2008, 79, 662-669.	1.4	30
796	Glycerol metabolism in severe falciparum malaria. Metabolism: Clinical and Experimental, 1994, 43, 887-892.	3.4	29
797	Plasmodium berghei Infection: Dichloroacetate Improves Survival in Rats with Lactic Acidosis. Experimental Parasitology, 1995, 80, 624-632.	1.2	29
798	Thrombocytopaenia in pregnant women with malaria on the Thai-Burmese border. Malaria Journal, 2008, 7, 209.	2.3	29
799	A Vaccine for Malaria. New England Journal of Medicine, 2011, 365, 1926-1927.	27.0	29
800	Opposite malaria and pregnancy effect on oral bioavailability of artesunate – a population pharmacokinetic evaluation. British Journal of Clinical Pharmacology, 2015, 80, 642-653.	2.4	29
801	Transmission of Artemisinin-Resistant Malaria Parasites to Mosquitoes under Antimalarial Drug Pressure. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	29
802	Non-adherence in non-inferiority trials: pitfalls and recommendations. BMJ, The, 2020, 370, m2215.	6.0	29
803	Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. American Journal of Tropical Medicine and Hygiene, 2008, 79, 378-84.	1.4	29
804	DANGERS OF HIGH-DOSE QUININE AND OVERHYDRATION IN SEVERE MALARIA. Lancet, The, 1985, 325, 1453-1454.	13.7	28
805	Clinical and laboratory studies of malaria and melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1988, 82, 15-20.	1.8	28
806	Abnormal circulatory control in falciparum malaria: the effects of antimalarial drugs. European Journal of Clinical Pharmacology, 1993, 44, 325-329.	1.9	28
807	Emergence in Vietnam of Streptococcus pneumoniae Resistant to Multiple Antimicrobial Agents as a Result of Dissemination of the Multiresistant Spain 23F -1 Clone. Antimicrobial Agents and Chemotherapy, 2002, 46, 3512-3517.	3.2	28
808	Clinical research: time for sensible global guidelines. Lancet, The, 2011, 377, 1553-1555.	13.7	28
809	Optimal sampling designs for estimation of Plasmodium falciparum clearance rates in patients treated with artemisinin derivatives. Malaria Journal, 2013, 12, 411.	2.3	28
810	Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers. British Journal of Clinical Pharmacology, 2017, 83, 2752-2766.	2.4	28

#	Article	IF	Citations
811	Perceptions of asymptomatic malaria infection and their implications for malaria control and elimination in Laos. PLoS ONE, 2018, 13, e0208912.	2.5	28
812	Optimal dosing of dihydroartemisinin-piperaquine for seasonal malaria chemoprevention in young children. Nature Communications, 2019, 10, 480.	12.8	28
813	Intragastric Mefloquine is Absorbed Rapidly in Patients with Cerebral Malaria. American Journal of Tropical Medicine and Hygiene, 1985, 34, 1028-1036.	1.4	28
814	Detection of Pseudomonas pseudomallei Antigen in Urine for the Diagnosis of Melioidosis. American Journal of Tropical Medicine and Hygiene, 1994, 51, 627-633.	1.4	28
815	Does Artesunate Prolong the Electrocardiograph QT Interval in Patients with Severe Malaria?. American Journal of Tropical Medicine and Hygiene, 2009, 80, 126-132.	1.4	28
816	Lipopolysaccharide heterogeneity among Burkholderia pseudomallei from different geographic and clinical origins. American Journal of Tropical Medicine and Hygiene, 2006, 74, 348-52.	1.4	28
817	Variation in virulence of dengue virus. Lancet, The, 1999, 354, 1401-1402.	13.7	27
818	Positive replication and linkage disequilibrium mapping of the chromosome 21q22.1 malaria susceptibility locus. Genes and Immunity, 2007, 8, 570-576.	4.1	27
819	Cost of increasing access to artemisinin combination therapy: the Cambodian experience. Malaria Journal, 2008, 7, 84.	2.3	27
820	Implementation of a reference standard and proficiency testing programme by the World Wide Antimalarial Resistance Network (WWARN). Malaria Journal, 2010, 9, 375.	2.3	27
821	Prognostic indicators in adults hospitalized with falciparum malaria in Western Thailand. Malaria Journal, 2013, 12, 229.	2.3	27
822	Lumefantrine and Desbutyl-Lumefantrine Population Pharmacokinetic-Pharmacodynamic Relationships in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria on the Thailand-Myanmar Border. Antimicrobial Agents and Chemotherapy, 2015, 59, 6375-6384.	3.2	27
823	Estimation of the $\langle i \rangle$ In Vivo $\langle i \rangle$ MIC of Cipargamin in Uncomplicated Plasmodium falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	27
824	Effectiveness and safety of 3 and 5Âday courses of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in an area of emerging artemisinin resistance in Myanmar. Malaria Journal, 2018, 17, 258.	2.3	27
825	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
826	A Simple Scoring System to Differentiate between Relapse and Re-Infection in Patients with Recurrent Melioidosis. PLoS Neglected Tropical Diseases, 2008, 2, e327.	3.0	27
827	Nitric oxides in plasma, urine, and cerebrospinal fluid in patients with severe falciparum malaria American Journal of Tropical Medicine and Hygiene, 1998, 59, 497-502.	1.4	27
828	Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. Lancet Infectious Diseases, The, 2022, 22, 867-878.	9.1	27

#	Article	IF	Citations
829	Lumbar puncture in cerebral malaria. Lancet, The, 1991, 338, 640-641.	13.7	26
830	Changes in the peripheral blood eosinophil count in falciparum malaria. Acta Tropica, 1991, 48, 243-246.	2.0	26
831	Quinine and mefloquine in the treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy. Annals of Tropical Medicine and Parasitology, 1998, 92, 643-653.	1.6	26
832	Why is it that antimalarial drug treatments do not always work?. Annals of Tropical Medicine and Parasitology, 1998, 92, 449-458.	1.6	26
833	Evaluation of Immunoglobulin M (IgM) and IgG Rapid Cassette Test Kits for Diagnosis of Melioidosis in an Area of Endemicity. Journal of Clinical Microbiology, 2004, 42, 3435-3437.	3.9	26
834	Double blind comparison of ibuprofen and paracetamol for adjunctive treatment of uncomplicated typhoid fever. Pediatric Infectious Disease Journal, 2004, 23, 226-230.	2.0	26
835	Artesunate–dapsone–proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 142-149.	1.8	26
836	A randomized comparison of oral chloramphenicol versus ofloxacin in the treatment of uncomplicated typhoid fever in Laos. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99, 451-458.	1.8	26
837	A liquid chromatographic–tandem mass spectrometric method for determination of artemether and its metabolite dihydroartemisinin in human plasma. Bioanalysis, 2009, 1, 37-46.	1.5	26
838	Laboratory prediction of the requirement for renal replacement in acute falciparum malaria. Malaria Journal, 2011, 10, 217.	2.3	26
839	A Small Amount of Fat Does Not Affect Piperaquine Exposure in Patients with Malaria. Antimicrobial Agents and Chemotherapy, 2011, 55, 3971-3976.	3.2	26
840	Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures. Clinical Infectious Diseases, 2018, 67, 1000-1007.	5.8	26
841	Investigating causal pathways in severe falciparum malaria: A pooled retrospective analysis of clinical studies. PLoS Medicine, 2019, 16, e1002858.	8.4	26
842	Fatal Plasmodium falciparum Malaria after an Inadequate Response to Quinine Treatment. Journal of Infectious Diseases, 1990, 161, 577-580.	4.0	25
843	Plasmodium berghei: Lactic acidosis and hypoglycaemia in a rodent model of severe malaria; effects of glucose, quinine, and dichloroacetate. Experimental Parasitology, 1991, 72, 123-133.	1.2	25
844	Fever in uncomplicated Plasmodium falciparum malaria: randomized double-â€~blind' comparison of ibuprofen and paracetamol treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 507-509.	1.8	25
845	The treatment of typhoid fever. Current Opinion in Infectious Diseases, 1996, 9, 298-302.	3.1	25
846	Lack of a significant adverse cardiovascular effect of combined quinine and mefloquine therapy for uncomplicated malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1997, 91, 694-696.	1.8	25

#	Article	IF	Citations
847	Plasmodium falciparum -Based Bioassay for Measurement of Artemisinin Derivatives in Plasma or Serum. Antimicrobial Agents and Chemotherapy, 2004, 48, 954-960.	3.2	25
848	Pharmacokinetics and Metabolism of the Antimalarial Piperaquine After Intravenous and Oral Single Doses to the Rat. Journal of Pharmaceutical Sciences, 2008, 97, 3400-3410.	3.3	25
849	Benefits of a Pharmacology Antimalarial Reference Standard and Proficiency Testing Program Provided by the Worldwide Antimalarial Resistance Network (WWARN). Antimicrobial Agents and Chemotherapy, 2014, 58, 3889-3894.	3.2	25
850	Artemisinin Resistance and Stage Dependency of Parasite Clearance in Falciparum Malaria. Journal of Infectious Diseases, 2019, 219, 1483-1489.	4.0	25
851	Efficacy and tolerability of artemisinin-based and quinine-based treatments for uncomplicated falciparum malaria in pregnancy: a systematic review and individual patient data meta-analysis. Lancet Infectious Diseases, The, 2020, 20, 943-952.	9.1	25
852	Prevalences of inherited red blood cell disorders in pregnant women of different ethnicities living along the Thailand-Myanmar border. Wellcome Open Research, 2017, 2, 72.	1.8	25
853	Red Cell Quinine Concentrations in Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 1983, 32, 456-460.	1.4	25
854	Hyponatremia in Severe Malaria: Evidence for an Appropriate Anti-diuretic Hormone Response to Hypovolemia. American Journal of Tropical Medicine and Hygiene, 2009, 80, 141-145.	1.4	25
855	COMBINATION TREATMENT FOR FALCIPARUM PROPHYLAXIS. Lancet, The, 1987, 329, 680-681.	13.7	24
856	Calcium and phosphate metabolism in acute falciparum malaria. Clinical Science, 1991, 81, 297-304.	4.3	24
857	Polymorphonuclear leucocyte elastase in Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 598-601.	1.8	24
858	Reactive nitrogen intermediates and outcome in severe adult malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 170-175.	1.8	24
859	Treatment of Severe Diphtheritic Myocarditis by Temporary Insertion of a Cardiac Pacemaker. Clinical Infectious Diseases, 2002, 35, 1425-1429.	5.8	24
860	Optimising operational use of artesunate-mefloquine: a randomised comparison of four treatment regimens. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2004, 98, 182-192.	1.8	24
861	Genetic Analysis of the Dihydrofolate Reductase-Thymidylate Synthase Gene from Geographically Diverse Isolates of <i>Plasmodium malariae</i> . Antimicrobial Agents and Chemotherapy, 2007, 51, 3523-3530.	3.2	24
862	Antimicrobial Disk Susceptibility Testing of Leptospira spp. Using Leptospira Vanaporn Wuthiekanun (LVW) Agar. American Journal of Tropical Medicine and Hygiene, 2015, 93, 241-243.	1.4	24
863	Sequestration and Red Cell Deformability as Determinants of Hyperlactatemia in Falciparum Malaria. Journal of Infectious Diseases, 2016, 213, 788-793.	4.0	24
864	Community perceptions of targeted anti-malarial mass drug administrations in two provinces in Vietnam: a quantitative survey. Malaria Journal, 2017, 16, 17.	2.3	24

#	Article	IF	Citations
865	Comparison of glucose-6 phosphate dehydrogenase status by fluorescent spot test and rapid diagnostic test in Lao PDR and Cambodia. Malaria Journal, 2018, 17, 243.	2.3	24
866	Altered expression of human monocyte Fc receptors in Plasmodium falciparum malaria. Infection and Immunity, 1984, 44, 623-626.	2.2	24
867	In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. American Journal of Tropical Medicine and Hygiene, 2004, 70, 395-7.	1.4	24
868	Absence of an interaction between artesunate and atovaquone - proguanil. European Journal of Clinical Pharmacology, 1999, 55, 469-474.	1.9	23
869	Urinary catecholamine excretion in tetanus. Anaesthesia, 2006, 61, 355-359.	3.8	23
870	Development and validation of an automated solid phase extraction and liquid chromatographic method for the determination of piperaquine in urine. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 213-218.	2.8	23
871	Serological Evidence for Increased Human Exposure to Burkholderia pseudomallei following the Tsunami in Southern Thailand. Journal of Clinical Microbiology, 2006, 44, 239-240.	3.9	23
872	Effect of magnesium sulphate on urinary catecholamine excretion in severe tetanus. Anaesthesia, 2008, 63, 719-725.	3.8	23
873	Pharmaceutical development and optimization of azithromycin suppository for paediatric use. International Journal of Pharmaceutics, 2013, 441, 218-226.	5.2	23
874	A multi-level spatial analysis of clinical malaria and subclinical Plasmodium infections in Pailin Province, Cambodia. Heliyon, 2017, 3, e00447.	3.2	23
875	Development of rectal self-emulsifying suspension of a moisture-labile water-soluble drug. International Journal of Pharmaceutics, 2018, 536, 283-291.	5.2	23
876	Point-of-care lung ultrasound for the detection of pulmonary manifestations of malaria and sepsis: An observational study. PLoS ONE, 2018, 13, e0204832.	2.5	23
877	Triple artemisinin-containing combination anti-malarial treatments should be implemented now to delay the emergence of resistance. Malaria Journal, 2019, 18, 338.	2.3	23
878	Pharmacokinetics of quinine and 3-hydroxyquinine in severe falciparum malaria with acute renal failure. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 69-72.	1.8	22
879	Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. British Journal of Clinical Pharmacology, 2000, 49, 445-452.	2.4	22
880	Cytokine Release by Lipopolysaccharideâ€Stimulated Whole Blood from Patients with Typhoid Fever. Journal of Infectious Diseases, 2002, 186, 240-245.	4.0	22
881	Comparison of chloroquine, sulfadoxine/pyrimethamine, mefloquine and mefloquine-artesunate for the treatment of falciparum malaria in Kachin State, North Myanmar. Tropical Medicine and International Health, 2004, 9, 1184-1190.	2.3	22
882	Importance of Collection Tube during Clinical Studies of Oseltamivir. Antimicrobial Agents and Chemotherapy, 2007, 51, 1835-1836.	3.2	22

#	Article	IF	CITATIONS
883	Costâ \in effectiveness of artesunate for the treatment of severe malaria. Tropical Medicine and International Health, 2009, 14, 332-337.	2.3	22
884	Counter Perspective: Artemisinin Resistance: Facts, Fears, and Fables. American Journal of Tropical Medicine and Hygiene, 2012, 87, 785-785.	1.4	22
885	Microsatellite genotyping of Plasmodium vivax infections and their relapses in pregnant and non-pregnant patients on the Thai-Myanmar border. Malaria Journal, 2013, 12, 275.	2.3	22
886	Population Pharmacokinetic Assessment of the Effect of Food on Piperaquine Bioavailability in Patients with Uncomplicated Malaria. Antimicrobial Agents and Chemotherapy, 2014, 58, 2052-2058.	3.2	22
887	Malaria: a molecular marker of artemisinin resistance. Lancet, The, 2014, 383, 1439-1440.	13.7	22
888	Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Journal of Antimicrobial Chemotherapy, 2014, 69, 3033-3040.	3.0	22
889	Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infectious Diseases, 2015, 15, 558.	2.9	22
890	A Randomized Controlled Trial of Three- versus Five-Day Artemether-Lumefantrine Regimens for Treatment of Uncomplicated Plasmodium falciparum Malaria in Pregnancy in Africa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	22
891	Concomitant Bacteremia in Adults With Severe Falciparum Malaria. Clinical Infectious Diseases, 2020, 71, e465-e470.	5.8	22
892	Protective effect of Mediterranean-type glucose-6-phosphate dehydrogenase deficiency against Plasmodium vivax malaria. ELife, 2021, 10, .	6.0	22
893	Improving statistical power in severe malaria genetic association studies by augmenting phenotypic precision. ELife, 2021, 10, .	6.0	22
894	An open label randomized controlled trial of tamoxifen combined with amphoteric B and fluconazole for cryptococcal meningitis. ELife, 2021, 10 , .	6.0	22
895	Mefloquine. BMJ: British Medical Journal, 1994, 308, 286-287.	2.3	22
896	Clinical trial of oral artesunate with or without high-dose primaquine for the treatment of vivax malaria in Thailand. American Journal of Tropical Medicine and Hygiene, 2003, 69, 14-8.	1.4	22
897	Effects of malaria heme products on red blood cell deformability. American Journal of Tropical Medicine and Hygiene, 2007, 77, 617-22.	1.4	22
898	The disposition and effects of two doses of dichloroacetate in adults with severe falciparum malaria. British Journal of Clinical Pharmacology, 1996, 41, 29-34.	2.4	21
899	Polymerase chain reaction for the detection of Burkholderia pseudomallei. Diagnostic Microbiology and Infectious Disease, 1997, 29, 121-127.	1.8	21
900	The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership. Malaria Journal, 2011, 10, 142.	2.3	21

#	Article	IF	CITATIONS
901	The reliability of the physical examination to guide fluid therapy in adults with severe falciparum malaria: an observational study. Malaria Journal, 2013, 12, 348.	2.3	21
902	Genetic Analysis of Primaquine Tolerance in a Patient with Relapsing Vivax Malaria. Emerging Infectious Diseases, 2013, 19, 802-805.	4.3	21
903	Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With <i>Plasmodium vivax</i> Malaria in Thailand. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-8.	2.5	21
904	Pharmacokinetics of Orally Administered Oseltamivir in Healthy Obese and Nonobese Thai Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 1615-1621.	3.2	21
905	History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia. Malaria Journal, 2016, 15, 240.	2.3	21
906	Fitness Loss under Amino Acid Starvation in Artemisinin-Resistant Plasmodium falciparum Isolates from Cambodia. Scientific Reports, 2018, 8, 12622.	3.3	21
907	A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis Wellcome Open Research, 2019, 4, 8.	1.8	21
908	Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives. Journal of Infectious Diseases, 2019, 220, 1178-1187.	4.0	21
909	Identification of the metabolites of ivermectin in humans. Pharmacology Research and Perspectives, 2021, 9, e00712.	2.4	21
910	Antiâ€malarial drug effects on parasite dynamics in vivax malaria. Malaria Journal, 2021, 20, 161.	2.3	21
911	Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong Subregion. Antimicrobial Agents and Chemotherapy, 2021, 65, e0112121.	3.2	21
912	Concentration-dependent mortality of chloroquine in overdose. ELife, 2020, 9, .	6.0	21
913	Aminoglycoside and Macrolide Resistance in <i>Burkholderia pseudomallei</i> . Antimicrobial Agents and Chemotherapy, 1999, 43, 2332-2332.	3.2	20
914	Diabetes Mellitus, Insulin, and Melioidosis in Thailand. Clinical Infectious Diseases, 2003, 36, e71-e72.	5.8	20
915	Malaria — Time to Act. New England Journal of Medicine, 2006, 355, 1956-1957.	27.0	20
916	Genetic Marker Suitable for Identification and Genotyping of Plasmodium ovale curtisi and Plasmodium ovale wallikeri. Journal of Clinical Microbiology, 2013, 51, 4213-4216.	3.9	20
917	Uncomplicated Plasmodium vivax malaria in pregnancy associated with mortality from acute respiratory distress syndrome. Malaria Journal, 2014, 13, 191.	2.3	20
918	The suitability of laboratory-bred Anopheles cracens for the production of Plasmodium vivax sporozoites. Malaria Journal, 2015, 14, 312.	2.3	20

#	Article	IF	Citations
919	Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar. Malaria Journal, 2017, 16, 480.	2.3	20
920	Enantiospecific pharmacokinetics and drug–drug interactions of primaquine and blood-stage antimalarial drugs. Journal of Antimicrobial Chemotherapy, 2018, 73, 3102-3113.	3.0	20
921	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Medicine, 2020, 17, e1003040.	8.4	20
922	Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether–lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 1395-1406.	9.1	20
923	Antibodies to the Vi capsule of Salmonella Typhi in the serum of typhoid patients and healthy control subjects from a typhoid endemic region. Journal of Infection in Developing Countries, 2008, 2, 308-12.	1.2	20
924	How can we do pharmacokinetic studies in the tropics?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 347-351.	1.8	19
925	Editorial: Clinical trials in tropical diseases: a politically incorrect view. Tropical Medicine and International Health, 2006, 11, 1483-1484.	2.3	19
926	Release of granzymes and chemokines in Thai patients with leptospirosis. Clinical Microbiology and Infection, 2007, 13, 433-436.	6.0	19
927	The â€~Unfinished Business' of Malaysia's Decolonisation: The Origins of the Guthrie â€~Dawn Raid'. Modern Asian Studies, 2010, 44, 919-960.	0.4	19
928	Temporal trends in severe malaria in Chittagong, Bangladesh. Malaria Journal, 2012, 11, 323.	2.3	19
929	Declining Malaria Transmission and Pregnancy Outcomes in Southern Mozambique. New England Journal of Medicine, 2015, 373, 1670-1671.	27.0	19
930	Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and nonâ€obese volunteers. British Journal of Clinical Pharmacology, 2016, 81, 1103-1112.	2.4	19
931	Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity. Journal of Infectious Diseases, 2019, 220, 100-104.	4.0	19
932	Tafenoquine â€" A Radical Improvement?. New England Journal of Medicine, 2019, 380, 285-286.	27.0	19
933	Epidemiology of Plasmodium vivax Malaria Infection in Nepal. American Journal of Tropical Medicine and Hygiene, 2018, 99, 680-687.	1.4	19
934	IN VITRO ANTIMALARIAL DRUG SUSCEPTIBILITY AND PFCRT MUTATION AMONG FRESH PLASMODIUM FALCIPARUM ISOLATES FROM THE LAO PDR (LAOS). American Journal of Tropical Medicine and Hygiene, 2007, 76, 245-250.	1.4	19
935	Hyponatremia in severe malaria: evidence for an appropriate anti-diuretic hormone response to hypovolemia. American Journal of Tropical Medicine and Hygiene, 2009, 80, 141-5.	1.4	19
936	The activity of amoxycillin/clavulanic acid against Pseudomonas pseudomallei. Journal of Antimicrobial Chemotherapy, 1989, 24, 1012-1013.	3.0	18

#	Article	IF	Citations
937	The pituitary-thyroid axis in severe falciparum malaria: evidence for depressed thyrotroph and thyroid gland function. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 330-335.	1.8	18
938	Antimalarial activity and interactions between quinine, dihydroquinine and 3-hydroxyquinine against Plasmodium falciparum in vitro. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1996, 90, 553-555.	1.8	18
939	The relationship between capillary and venous concentrations of the antimalarial drug lumefantrine (benflumetol). Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 564-565.	1.8	18
940	The Influence of Lamellar Orientation on Corneal Material Behavior: Biomechanical and Structural Changes in an Avian Corneal Disorder., 2011, 52, 1243.		18
941	Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention. Science Translational Medicine, 2014, 6, 260ra147.	12.4	18
942	Population Pharmacokinetics of Intravenous Artesunate: A Pooled Analysis of Individual Data From Patients With Severe Malaria. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-9.	2.5	18
943	The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin–piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos. Malaria Journal, 2018, 17, 405.	2.3	18
944	Epidemiological Characteristics, Ventilator Management, and Clinical Outcome in Patients Receiving Invasive Ventilation in Intensive Care Units from 10 Asian Middle-Income Countries (PRoVENT-iMiC): An International, Multicenter, Prospective Study. American Journal of Tropical Medicine and Hygiene, 2021, , .	1.4	18
945	Emergence of Artemisinin-Resistant <i>Plasmodium falciparum</i> in East Africa. New England Journal of Medicine, 2021, 385, 1231-1232.	27.0	18
946	A Retrospective Analysis of the Haemodynamic and Metabolic Effects of Fluid Resuscitation in Vietnamese Adults with Severe Falciparum Malaria. PLoS ONE, 2011, 6, e25523.	2.5	18
947	Rapid Clinical Assessment to Facilitate the Triage of Adults with Falciparum Malaria, a Retrospective Analysis. PLoS ONE, 2014, 9, e87020.	2.5	18
948	Acute Encephalopathy Associated with Influenza A Infection in Adults. Emerging Infectious Diseases, 2010, 16, 139-142.	4.3	18
949	Prolongation of the QTc interval in African children treated for falciparum malaria American Journal of Tropical Medicine and Hygiene, 1998, 59, 503-503.	1.4	18
950	Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria?. American Journal of Tropical Medicine and Hygiene, 2009, 80, 126-32.	1.4	18
951	Genome fingerprinting by pulsed-field gel electrophoresis of isolates of Burkholderia pseudomallei from patients with melioidosis in Thailand. Acta Tropica, 2000, 74, 187-191.	2.0	17
952	Editorial: Maternal malaria: time for action. Tropical Medicine and International Health, 2003, 8, 485-487.	2.3	17
953	Field Evaluation of a Novel Colorimetric Method—Double-Site Enzyme-Linked Lactate Dehydrogenase Immunodetection Assay—To Determine Drug Susceptibilities of Plasmodium falciparum Clinical Isolates from Northwestern Thailand. Antimicrobial Agents and Chemotherapy, 2004, 48, 1426-1429.	3.2	17
954	Induction of the vascular endothelial growth factor pathway in the brain of adults with fatal falciparum malaria is a nonâ€specific response to severe disease. Histopathology, 2010, 57, 282-294.	2.9	17

#	Article	IF	Citations
955	Efficacy of artemether-lumefantrine, the nationally-recommended artemisinin combination for the treatment of uncomplicated falciparum malaria, in southern Laos. Malaria Journal, 2012, 11, 184.	2.3	17
956	Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations. Malaria Journal, 2012, 11, 137.	2.3	17
957	Quality assurance of drugs used in clinical trials: proposal for adapting guidelines. BMJ: British Medical Journal, 2015, 350, h602.	2.3	17
958	Treatment of Ebola. New England Journal of Medicine, 2015, 372, 1673-1674.	27.0	17
959	Pharmacokinetic-Pharmacodynamic Assessment of the Hepatic and Bone Marrow Toxicities of the New Trypanoside Fexinidazole. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3. 2	17
960	Amino acid derangements in adults with severe falciparum malaria. Scientific Reports, 2019, 9, 6602.	3.3	17
961	Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. Journal of Infectious Diseases, 2019, 220, 448-456.	4.0	17
962	Setting Our Sights on Infectious Diseases. ACS Infectious Diseases, 2020, 6, 3-13.	3.8	17
963	Dihydrofolate-Reductase Mutations in Plasmodium knowlesi Appear Unrelated to Selective Drug Pressure from Putative Human-To-Human Transmission in Sabah, Malaysia. PLoS ONE, 2016, 11, e0149519.	2.5	17
964	The treatment of falciparum malaria. Parasitology Today, 1988, 4, 10-14.	3.0	16
965	Blood culture techniques for the diagnosis of melioidosis. European Journal of Clinical Microbiology and Infectious Diseases, 1990, 9, 654-658.	2.9	16
966	Spiramycin does not potentiate quinine treatment of falciparum malaria in pregnancy. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 305-306.	1.8	16
967	Neurological Dysfunction Following Malaria: Disease- or Drug-Related?. Clinical Infectious Diseases, 2000, 30, 836-836.	5.8	16
968	Misattribution of Central Nervous System Dysfunction to Artesunate. Clinical Infectious Diseases, 2005, 41, 1687-1688.	5.8	16
969	Toxic brainstem encephalopathy after artemisinin treatment for breast cancer. Annals of Neurology, 2006, 59, 725-726.	5.3	16
970	Diagnostic and Treatment Difficulties of Pyelonephritis in Pregnancy in Resource-Limited Settings. American Journal of Tropical Medicine and Hygiene, 2010, 83, 1322-1329.	1.4	16
971	No Evidence for Spread of Plasmodium falciparum Artemisinin Resistance to Savannakhet Province, Southern Laos. American Journal of Tropical Medicine and Hygiene, 2012, 86, 403-408.	1.4	16
972	Optimal designs for population pharmacokinetic studies of the partner drugs co-administered with artemisinin derivatives in patients with uncomplicated falciparum malaria. Malaria Journal, 2012, 11, 143.	2.3	16

#	Article	IF	CITATIONS
973	The Effect of Carbohydrate Ingestion on Performance during a Simulated Soccer Match. Nutrients, 2013, 5, 5193-5204.	4.1	16
974	Why Do Some Primate Malarias Relapse?. Trends in Parasitology, 2016, 32, 918-920.	3.3	16
975	Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	16
976	Split dosing of artemisinins does not improve antimalarial therapeutic efficacy. Scientific Reports, 2017, 7, 12132.	3.3	16
977	Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria. PLoS ONE, 2017, 12, e0169307.	2.5	16
978	Real time PCR detection of common CYP2D6 genetic variants and its application in a Karen population study. Malaria Journal, 2018, 17, 427.	2.3	16
979	Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2020, 18, 138.	5.5	16
980	Why is WHO failing women with falciparum malaria in the first trimester of pregnancy?. Lancet, The, 2020, 395, 779.	13.7	16
981	A case-control auditory evaluation of patients treated with artemether-lumefantrine. American Journal of Tropical Medicine and Hygiene, 2006, 74, 211-4.	1.4	16
982	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16
983	Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	16
984	Activation of cellular immune responses in melioidosis patients as assessed by urinary neopterin. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 583-584.	1.8	15
985	Sulfadoxine-pyrimethamine for the treatment of malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 556-557.	1.8	15
986	Optimal regimens of parenteral quinine. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 462-463.	1.8	15
987	Fluoroquinolone antibiotics in children with multidrug resistant typhoid. Lancet, The, 1996, 348, 547.	13.7	15
988	The resistance to physiological shear stresses of the erythrocytic rosettes formed by cells infected with Plasmodium falciparum. Annals of Tropical Medicine and Parasitology, 2000, 94, 219-226.	1.6	15
989	Malaria in Injection Drug Abusers in Vietnam. Clinical Infectious Diseases, 2002, 34, 1317-1322.	5.8	15
990	Alanine metabolism in acute falciparum malaria. Tropical Medicine and International Health, 2002, 7, 911-918.	2.3	15

#	Article	IF	CITATIONS
991	Comparative trial of short-course ofloxacin for uncomplicated typhoid fever in Vietnamese children. Annals of Tropical Paediatrics, 2005, 25, 17-22.	1.0	15
992	Susceptibility of bacterial isolates from communityâ€acquired infections in subâ€Saharan Africa and Asia to macrolide antibiotics. Tropical Medicine and International Health, 2011, 16, 1192-1205.	2.3	15
993	New global estimates of malaria deaths. Lancet, The, 2012, 380, 559-560.	13.7	15
994	Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. Journal of Antimicrobial Chemotherapy, 2013, 68, 697-707.	3.0	15
995	The role of previously unmeasured organic acids in the pathogenesis of severe malaria. Critical Care, 2015, 19, 317.	5.8	15
996	An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. BMC Medicine, 2016, 14, 171.	5.5	15
997	Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment. Scientific Reports, 2018, 8, 17545.	3.3	15
998	Comparison of Capillary Whole Blood, Venous Whole Blood, and Plasma Concentrations of Mefloquine, Halofantrine, and Desbutyl-Halofantrine Measured by High-Performance Liquid Chromatography. American Journal of Tropical Medicine and Hygiene, 1994, 51, 778-784.	1.4	15
999	Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. ELife, 2019, 8, .	6.0	15
1000	A hospital-based study of bloodstream infections in febrile patients in Dhulikhel Hospital Kathmandu University Teaching Hospital, Nepal. Southeast Asian Journal of Tropical Medicine and Public Health, 2006, 37, 351-6.	1.0	15
1001	Quantitation of cell-derived microparticles in plasma using flow rate based calibration. Southeast Asian Journal of Tropical Medicine and Public Health, 2008, 39, 146-53.	1.0	15
1002	Clinical Management of Chloroquine-Resistant <i>Plasmodium Falciparum</i> Malaria in Southeast Asia. Tropical Doctor, 1983, 13, 153-158.	0.5	14
1003	Comparative effects of quinine and quinidine on glucose metabolism in healthy volunteers British Journal of Clinical Pharmacology, 1990, 30, 397-403.	2.4	14
1004	Government and business divided: Malaya, 1945–57. Journal of Imperial and Commonwealth History, 1994, 22, 251-274.	0.3	14
1005	Differences in Genomic Macrorestriction Patterns of Arabinoseâ€Positive (<i>Burkholderia) Tj ETQq1 1 0.784314 Immunology, 1999, 43, 625-630.</i>	rgBT /Ove 1.4	erlock 10 T 14
1006	Malaria epidemic in Burundi. Lancet, The, 2001, 357, 1046-1047.	13.7	14
1007	Development and Validation of a Solid-Phase Extraction-Liquid Chromatographic Method for Determination of Amoxicillin in Plasma. Therapeutic Drug Monitoring, 2005, 27, 503-508.	2.0	14
1008	Pharmacokinetic and pharmacodynamic assessment of co-amoxiclav in the treatment of melioidosis. Journal of Antimicrobial Chemotherapy, 2006, 58, 1215-1220.	3.0	14

#	Article	IF	Citations
1009	Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria. PLoS Medicine, 2008, 5, e227.	8.4	14
1010	Erythropoietin and its receptors in the brainstem of adults with fatal falciparum malaria. Malaria Journal, 2009, 8, 261.	2.3	14
1011	Towards optimal design of anti-malarial pharmacokinetic studies. Malaria Journal, 2009, 8, 189.	2.3	14
1012	The role of mathematical modelling in guiding the science and economics of malaria elimination. International Health, 2010, 2, 239-246.	2.0	14
1013	Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria. Malaria Journal, 2011, 10, 181.	2.3	14
1014	An Open-Label Crossover Study To Evaluate Potential Pharmacokinetic Interactions between Oral Oseltamivir and Intravenous Zanamivir in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2011, 55, 4050-4057.	3.2	14
1015	Correlation of Susceptibility of Cryptococcus neoformans to Amphotericin B with Clinical Outcome. Antimicrobial Agents and Chemotherapy, 2011, 55, 5624-5630.	3.2	14
1016	Reconstructing Europe through Rejuvenating Empire: the British, French, and Dutch Experiences Compared. Past and Present, 2011, 210, 211-236.	0.7	14
1017	Participants' perceptions and understanding of a malaria clinical trial in Bangladesh. Malaria Journal, 2014, 13, 217.	2.3	14
1018	Evaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma. Drug Safety, 2019, 42, 769-784.	3.2	14
1019	Associations Between Restrictive Fluid Management and Renal Function and Tissue Perfusion in Adults With Severe Falciparum Malaria: A Prospective Observational Study. Journal of Infectious Diseases, 2020, 221, 285-292.	4.0	14
1020	Holding Back the Tide: Liverpool Shipping, Gentlemanly Capitalism and Intra-Asian Trade in the Twentieth Century. , 2015, , 218-240.		14
1021	Prevalences of inherited red blood cell disorders in pregnant women of different ethnicities living along the Thailand-Myanmar border. Wellcome Open Research, 0, 2, 72.	1.8	14
1022	Combined Molecular and Clinical Assessment of Plasmodium falciparum Antimalarial Drug Resistance in the Lao People's Democratic Republic (Laos). American Journal of Tropical Medicine and Hygiene, 2007, 77, 36-43.	1.4	14
1023	Potential herd protection against Plasmodium falciparum infections conferred by mass antimalarial drug administrations. ELife, 2019, 8, .	6.0	14
1024	Have we really failed to roll back malaria?. Lancet, The, 2022, 399, 799-800.	13.7	14
1025	PROGNOSTIC VALUE OF CSF LACTATE IN CEREBRAL MALARIA. Lancet, The, 1987, 329, 1261.	13.7	13
1026	Rosetting characteristics of uninfected erythrocytes from healthy individuals and malaria patients. Annals of Tropical Medicine and Parasitology, 1998, 92, 45-56.	1.6	13

#	Article	IF	Citations
1027	What is the future of exchange transfusion in severe malaria?. Journal of Infection, 1999, 39, 185-186.	3.3	13
1028	Plasmodium vivax: Polymerase Chain Reaction Amplification Artifacts Limit the Suitability of pvgam1 as a Genetic Marker. Experimental Parasitology, 2001, 99, 175-179.	1.2	13
1029	Sulfadoxine-pyrimethamine for uncomplicated falciparum malaria: Sulfadoxine-pyrimethamine is not working in Malawi. BMJ: British Medical Journal, 2004, 328, 1259.1.	2.3	13
1030	Early treatment failure in severe malaria resulting from abnormally low plasma quinine concentrations. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2006, 100, 184-186.	1.8	13
1031	Central venous catheter use in severe malaria: time to reconsider the World Health Organization guidelines?. Malaria Journal, 2011, 10, 342.	2.3	13
1032	Quantification of the anti-influenza drug zanamivir in plasma using high-throughput HILIC–MS/MS. Bioanalysis, 2011, 3, 157-165.	1.5	13
1033	A High Burden of Respiratory Syncytial Virus Associated Pneumonia in Children Less than Two Years of Age in a South East Asian Refugee Population. PLoS ONE, 2012, 7, e50100.	2.5	13
1034	A Population Survey of the Glucose-6-Phosphate Dehydrogenase (G6PD) 563C>T (Mediterranean) Mutation in Afghanistan. PLoS ONE, 2014, 9, e88605.	2.5	13
1035	Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort. Malaria Journal, 2015, 14, 221.	2.3	13
1036	The threat of artemisinin resistant malaria in Southeast Asia. Travel Medicine and Infectious Disease, 2016, 14, 548-550.	3.0	13
1037	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
1038	Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine. Royal Society Open Science, 2021, 8, 210235.	2.4	13
1039	Association between Subclinical Malaria Infection and Inflammatory Host Response in a Pre-Elimination Setting. PLoS ONE, 2016, 11, e0158656.	2.5	13
1040	Chloroquine–Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1782-1787.	1.4	13
1041	Antimalarial Drug Susceptibility of Plasmodium vivax in the Republic of Korea. American Journal of Tropical Medicine and Hygiene, 2009, 80, 902-904.	1.4	13
1042	In vitro antimalarial drug susceptibility and pfcrt mutation among fresh Plasmodium falciparum isolates from the Lao PDR (Laos). American Journal of Tropical Medicine and Hygiene, 2007, 76, 245-50.	1.4	13
1043	Accurate and Sensitive Detection of Plasmodium Species in Humans by Use of the Dihydrofolate Reductase-Thymidylate Synthase Linker Region. Journal of Clinical Microbiology, 2010, 48, 3735-3737.	3.9	12
1044	Computational analysis of binding between malarial dihydrofolate reductases and anti-folates. Malaria Journal, 2010, 9, 65.	2.3	12

#	Article	IF	Citations
1045	Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan. Malaria Journal, 2013, 12, 96.	2.3	12
1046	Cost of treating inpatient falciparum malaria on the Thai-Myanmar border. Malaria Journal, 2014, 13, 416.	2.3	12
1047	Protein profiling of mefloquine resistant Plasmodium falciparum using mass spectrometry-based proteomics. International Journal of Mass Spectrometry, 2015, 391, 82-92.	1,5	12
1048	Geographic distribution of amino acid mutations in DHFR and DHPS in Plasmodium vivax isolates from Lao PDR, India and Colombia. Malaria Journal, 2016, 15, 484.	2.3	12
1049	A Randomized Comparison of Chloroquine Versus Dihydroartemisinin–Piperaquine for the Treatment of Plasmodium vivax Infection in Vietnam. American Journal of Tropical Medicine and Hygiene, 2016, 94, 879-885.	1.4	12
1050	Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia. AAPS Journal, 2017, 19, 1842-1854.	4.4	12
1051	Disease Severity and Effective Parasite Multiplication Rate in Falciparum Malaria. Open Forum Infectious Diseases, 2017, 4, ofx169.	0.9	12
1052	Characterizing Blood-Stage Antimalarial Drug MIC Values <i>In Vivo</i> Using Reinfection Patterns. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
1053	Genetic polymorphisms in the circumsporozoite protein of Plasmodium malariae show a geographical bias. Malaria Journal, 2018, 17, 269.	2.3	12
1054	Pharmacokinetics of Oral Tenofovir Disoproxil Fumarate in Pregnancy and Lactation: A Systematic Review. Antiviral Therapy, 2019, 24, 529-540.	1.0	12
1055	T-cell responsiveness in severe Plasmodium falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1983, 77, 671-672.	1.8	11
1056	The metabolic response to rapid intravenous glucose injection in acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1991, 85, 189-193.	1.8	11
1057	Progression of skeletal muscle damage during treatment of severe falciparum malaria. Acta Tropica, 2000, 76, 271-276.	2.0	11
1058	Evidence behind the WHO Guidelines: Hospital Care for Children: Efficacy and Safety of Artemisinin Derivatives in Children with Malaria. Journal of Tropical Pediatrics, 2005, 52, 78-82.	1.5	11
1059	In Vitro-Clinical Correlations for Amphotericin B Susceptibility in AIDS-Associated Cryptococcal Meningitis. Antimicrobial Agents and Chemotherapy, 2007, 51, 343-345.	3.2	11
1060	Cerebral calpain in fatal falciparum malaria. Neuropathology and Applied Neurobiology, 2007, 33, 179-192.	3.2	11
1061	Protein-based signatures of functional evolution in Plasmodium falciparum. BMC Evolutionary Biology, 2011, 11, 257.	3.2	11
1062	Screening paediatric rectal forms of azithromycin as an alternative to oral or injectable treatment. International Journal of Pharmaceutics, 2012, 436, 624-630.	5.2	11

#	Article	IF	Citations
1063	Ethics, Economics, and the Use of Primaquine to Reduce Falciparum Malaria Transmission in Asymptomatic Populations. PLoS Medicine, 2014, 11, e1001704.	8.4	11
1064	Comparative genome-wide analysis and evolutionary history of haemoglobin-processing and haem detoxification enzymes in malarial parasites. Malaria Journal, 2016, 15, 51.	2.3	11
1065	Pharmacokinetic Study of Rectal Artesunate in Children with Severe Malaria in Africa. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	11
1066	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 2021, 6, 64.	1.8	11
1067	Guidelines should not pool evidence from uncomplicated and severe COVID-19. Lancet, The, 2021, 397, 1262-1263.	13.7	11
1068	A randomized controlled trial of dihydroartemisinin-piperaquine, artesunate-mefloquine and extended artemether-lumefantrine treatments for malaria in pregnancy on the Thailand-Myanmar border. BMC Medicine, 2021, 19, 132.	5 . 5	11
1069	Personalised randomised controlled trial designsâ€"a new paradigm to define optimal treatments for carbapenem-resistant infections. Lancet Infectious Diseases, The, 2021, 21, e175-e181.	9.1	11
1070	Mathematical Models for a New Era of Malaria Eradication. PLoS Medicine, 2008, 5, e231.	8.4	11
1071	Combined molecular and clinical assessment of Plasmodium falciparum antimalarial drug resistance in the Lao People's Democratic Republic (Laos). American Journal of Tropical Medicine and Hygiene, 2007, 77, 36-43.	1.4	11
1072	Defining the burden of febrile illness in rural South and Southeast Asia: an open letter to announce the launch of the Rural Febrile Illness project. Wellcome Open Research, 0, 6, 64.	1.8	11
1073	Stopping prereferral rectal artesunate — a grave error. BMJ Global Health, 2022, 7, e010006.	4.7	11
1074	The Frustrations of Development: British Business and the Late Colonial State in Malaya, 1945–57. Journal of Southeast Asian Studies, 1997, 28, 103-119.	0.1	10
1075	Factors affecting the pharmacokinetics of parenteral chloramphenicol in enteric fever. Journal of Antimicrobial Chemotherapy, 1997, 40, 91-98.	3.0	10
1076	Diagnosis and management of malaria by rural community health providers in the Lao People's Democratic Republic (Laos). Tropical Medicine and International Health, 2007, 12, 540-546.	2.3	10
1077	Investigation of porous graphitic carbon at high-temperature liquid chromatography with evaporative light scattering detection for the analysis of the drug combination artesunateâ€"Azithromycin for the treatment of severe malaria. Journal of Chromatography A, 2010, 1217, 75-81.	3.7	10
1078	Population Pharmacokinetic and Pharmacodynamic Properties of Intramuscular Quinine in Tanzanian Children with Severe Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2013, 57, 775-783.	3.2	10
1079	Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria – a proposed model-derived age-based regimen for sub-Saharan Africa. BMC Medicine, 2018, 16, 11.	5.5	10
1080	Determinants of Primaquine and Carboxyprimaquine Exposures in Children and Adults with Plasmodium vivax Malaria. Antimicrobial Agents and Chemotherapy, 2021, 65, e0130221.	3.2	10

#	Article	IF	Citations
1081	Counterfeit and Substandard Anti-infectives in Developing Countries. , 2010, , 413-443.		10
1082	NO EVIDENCE OF CARDIOTOXICITY OF ATOVAQUONE-PROGUANIL ALONE OR IN COMBINATION WITH ARTESUNATE. American Journal of Tropical Medicine and Hygiene, 2005, 73, 267-268.	1.4	10
1083	Defining and Defeating the Intolerable Burden of Malaria III. Progress and Perspectives. American Journal of Tropical Medicine and Hygiene, 2007, 77, i-ii.	1.4	10
1084	Characterization of "Yaa Chud" Medicine on the Thailand-Myanmar border: selecting for drug-resistant malaria and threatening public health. American Journal of Tropical Medicine and Hygiene, 2008, 79, 662-9.	1.4	10
1085	MALARIOLOGY. Lancet, The, 1993, 341, 793.	13.7	9
1086	Capitalism and Counter-insurgency? Business and Government in the Malayan Emergency, 1948-57. Modern Asian Studies, 1998, 32, 149-177.	0.4	9
1087	Effects of cigarette smoking on quinine pharmacokinetics in malaria. European Journal of Clinical Pharmacology, 2002, 58, 315-319.	1.9	9
1088	A randomized comparison of oral chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated Plasmodium falciparum malaria in Laos. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2003, 97, 343-344.	1.8	9
1089	Sharing malarias. Lancet, The, 2004, 363, 1006.	13.7	9
1090	Improving the availability of artesunate for treatment of severe malaria. Medical Journal of Australia, 2006, 184, 3-4.	1.7	9
1091	Identification of an isomer impurity in piperaquine drug substance. Journal of Chromatography A, 2006, 1135, 166-169.	3.7	9
1092	The Affordable Medicines Facility—malaria: killing it slowly. Lancet, The, 2012, 380, 1889-1890.	13.7	9
1093	The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study. Malaria Journal, 2017, 16, 444.	2.3	9
1094	Infectivity of Chronic Malaria Infections and Its Consequences for Control and Elimination. Clinical Infectious Diseases, 2018, 67, 295-302.	5.8	9
1095	Acidosis and acute kidney injury in severe malaria. Malaria Journal, 2018, 17, 128.	2.3	9
1096	Sequential Open-Label Study of the Safety, Tolerability, and Pharmacokinetic Interactions between Dihydroartemisinin-Piperaquine and Mefloquine in Healthy Thai Adults. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	9
1097	Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Human Vaccines and Immunotherapeutics, 2020, 16, 33-41.	3.3	9
1098	Falciparum but not vivax malaria increases the risk of hypertensive disorders of pregnancy in women followed prospectively from the first trimester. BMC Medicine, 2021, 19, 98.	5.5	9

#	Article	IF	Citations
1099	Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. American Journal of Tropical Medicine and Hygiene, 2009, 80, 902-4.	1.4	9
1100	Host vascular endothelial growth factor is trophic for Plasmodium falciparum-infected red blood cells. Asian Pacific Journal of Allergy and Immunology, 2008, 26, 37-45.	0.4	9
1101	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5. 5	9
1102	Pharmacokinetic considerations in seasonal malaria chemoprevention. Trends in Parasitology, 2022, 38, 673-682.	3.3	9
1103	Systemic lupus erythematosus and nephritis: severe relapse with disappearance of antinuclear antibodies BMJ: British Medical Journal, 1980, 281, 194-195.	2.3	8
1104	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. Clinical Science, 2001, 100, 101-110.	4.3	8
1105	Protein and energy metabolism in chronic bacterial infection: studies in melioidosis. Clinical Science, 2001, 100, 101.	4.3	8
1106	The influence of body weight on the pharmacokinetics of mefloquine. British Journal of Clinical Pharmacology, 2002, 53, 337-338.	2.4	8
1107	Simultaneous Determination of Artemether and Azithromycin in Suppositories by Reversed Phase HPLC. Analytical Letters, 2011, 44, 2732-2743.	1.8	8
1108	Modelling malaria elimination on the internet. Malaria Journal, 2011, 10, 191.	2.3	8
1109	Rectal pH in Well and Unwell Infants. Journal of Tropical Pediatrics, 2012, 58, 311-313.	1.5	8
1110	Comparison of Oseltamivir and Oseltamivir Carboxylate Concentrations in Venous Plasma, Venous Blood, and Capillary Blood in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2013, 57, 2858-2862.	3.2	8
1111	Study protocol for a randomised controlled double-blinded trial of the dose-dependent efficacy and safety of primaquine for clearance of gametocytes in children with uncomplicated falciparum malaria in Uganda. BMJ Open, 2013, 3, e002759.	1.9	8
1112	Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction. Malaria Journal, 2016, 15, 121.	2.3	8
1113	Preformulation studies of ceftriaxone for pediatric non-parenteral administration as an alternative to existing injectable formulations. European Journal of Pharmaceutical Sciences, 2017, 104, 382-392.	4.0	8
1114	Intracluster correlation coefficients in the Greater Mekong Subregion for sample size calculations of cluster randomized malaria trials. Malaria Journal, 2019, 18, 428.	2.3	8
1115	Utility of Plasmodium falciparum DNA from rapid diagnostic test kits for molecular analysis and whole genome amplification. Malaria Journal, 2020, 19, 193.	2.3	8
1116	Does hydroxychloroquine still have any role in the COVID-19 pandemic?. Expert Opinion on Pharmacotherapy, 2021, 22, 1257-1266.	1.8	8

#	Article	lF	CITATIONS
1117	Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial. Lancet Infectious Diseases, The, 2021, 21, 1579-1589.	9.1	8
1118	Cerebral perfusion in cerebral malaria. Critical Care Medicine, 1999, 27, 478-479.	0.9	8
1119	Neutralizing Antibodies against Plasmodium falciparum Associated with Successful Cure after Drug Therapy. PLoS ONE, 2016, 11, e0159347.	2.5	8
1120	Spend wisely to eliminate malaria. Lancet Infectious Diseases, The, 2022, 22, e171-e175.	9.1	8
1121	Plasma concentrations and toxicity of chloroquine after slow intravenous infusion in patients with falciparum malaria. Annals of Tropical Medicine and Parasitology, 1987, 81, 79-84.	1.6	7
1122	The use of bone marrow culture for the diagnosis of melioidosis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 585-587.	1.8	7
1123	In-vivo Platelet Activation and Anomalous Thrombospondin Levels in Severe Falciparum Malaria. Platelets, 1992, 3, 195-200.	2.3	7
1124	Absorption of intramuscular phenobarbitone in children with severe falciparum malaria. European Journal of Clinical Pharmacology, 1992, 42, 107-110.	1.9	7
1125	British Business Groups and the Early Years of Malayan/Malaysian Independence, 1957-65. Asia Pacific Business Review, 2000, 7, 155-176.	2.9	7
1126	Monitoring Antimalarial Drug Efficacy. Clinical Infectious Diseases, 2004, 38, 1192-1193.	5.8	7
1127	Overestimating resistance in field testing of malaria parasites: simple methods for estimating high EC50 values using a Bayesian approach. Malaria Journal, 2007, 6, 4.	2.3	7
1128	The role of mathematical modelling in malaria elimination and eradication (Comment on: Can malaria) Tj ETQq0 0	01.8BT/O	verlock 10 Tf
1129	Cost-Effectiveness of Pre-Referral Antimalarial, Antibacterial, and Combined Rectal Formulations for Severe Febrile Illness. PLoS ONE, 2010, 5, e14446.	2.5	7
1130	Malaria in the Post-Partum Period; a Prospective Cohort Study. PLoS ONE, 2013, 8, e57890.	2.5	7
1131	Reply to Meshnick and Hastings et al. Clinical Infectious Diseases, 2016, 63, 1528-1529.	5.8	7
1132	The Consequences of Treating Asymptomatic Malaria Parasitemia. Clinical Infectious Diseases, 2017, 64, 654-655.	5.8	7
1133	Genetic dissociation of three antigenic genes in Plasmodium ovale curtisi and Plasmodium ovale wallikeri. PLoS ONE, 2019, 14, e0217795.	2.5	7
1134	The rise and fall of long-latency <i>Plasmodium vivax</i> . Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 163-168.	1.8	7

#	Article	IF	CITATIONS
1135	Reduced Cardiac Index Reserve and Hypovolemia in Severe Falciparum Malaria. Journal of Infectious Diseases, 2020, 221, 1518-1527.	4.0	7
1136	Taking on Plasmodium vivax malaria: A timely and important challenge. PLoS Medicine, 2021, 18, e1003593.	8.4	7
1137	Clustering of malaria in households in the Greater Mekong Subregion: operational implications for reactive case detection. Malaria Journal, 2021, 20, 351.	2.3	7
1138	Clinical malaria in the tropics. Medical Journal of Australia, 1993, 159, 197-203.	1.7	7
1139	Platelets and Blood Coagulation in Human Malaria. Tropical Medicine, 2004, , 249-276.	0.3	7
1140	The assessment of antimalarial drug efficacy in vivo. Trends in Parasitology, 2022, 38, 660-672.	3.3	7
1141	Encephalitis, Not Cerebral Malaria, Is Likely Cause of Coma with Negative Blood Smears. Journal of Infectious Diseases, 1992, 166, 1195-1196.	4.0	6
1142	Early vomiting of mefloquine in children with malaria is not modified by the timing of antipyretic treatment. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 562-563.	1.8	6
1143	Combination Antibiotic Therapy for Severe Melioidosis. Clinical Infectious Diseases, 1999, 28, 410-410.	5.8	6
1144	Sporotrichosis, Plain of Jars, Lao People's Democratic Republic. Emerging Infectious Diseases, 2005, 11, 1496-1497.	4.3	6
1145	Artesunate versus quinine for severe falciparum malaria – Authors' reply. Lancet, The, 2006, 367, 111-112.	13.7	6
1146	Artesunate Dosing in Severe Falciparum Malaria. Journal of Infectious Diseases, 2012, 206, 618-619.	4.0	6
1147	Development of NIRS method for quality control of drug combination artesunate–azithromycin for the treatment of severe malaria. Journal of Pharmaceutical and Biomedical Analysis, 2012, 67-68, 10-15.	2.8	6
1148	Treatment of Suspected Hyper-Reactive Malarial Splenomegaly (HMS) in Pregnancy with Mefloquine. American Journal of Tropical Medicine and Hygiene, 2014, 90, 609-611.	1.4	6
1149	Thiamin supplementation does not reduce the frequency of adverse events after anti-malarial therapy among patients with falciparum malaria in southern Laos. Malaria Journal, 2014, 13, 275.	2.3	6
1150	Statistical Power Calculations for Mixed Pharmacokinetic Study Designs Using a Population Approach. AAPS Journal, 2014, 16, 1110-1118.	4.4	6
1151	Quantification of the antimalarial drug pyronaridine in whole blood using LC–MS/MS — Increased sensitivity resulting from reduced non-specific binding. Journal of Pharmaceutical and Biomedical Analysis, 2017, 146, 214-219.	2.8	6
1152	Doseâ€Exposureâ€Response Relationship of the Investigational Antiâ€Interleukinâ€13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma. Clinical Pharmacology and Therapeutics, 2018, 103, 826-835.	4.7	6

#	Article	IF	Citations
1153	No evidence that chloroquine or hydroxychloroquine induce hemolysis in G6PD deficiency. Blood Cells, Molecules, and Diseases, 2020, 85, 102484.	1.4	6
1154	Triple artemisinin-based combination therapies for malaria: proceed with caution – Authors' reply. Lancet, The, 2020, 396, 1976-1977.	13.7	6
1155	Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparumÂhave only a transient impact on Plasmodium vivax: Findings from randomised controlled trials. PLoS ONE, 2020, 15, e0228190.	2.5	6
1156	Genetic Variability of Plasmodium malariae dihydropteroate synthase (dhps) in Four Asian Countries. PLoS ONE, 2014, 9, e93942.	2.5	6
1157	What causes malaria anemia?. Blood, 2022, 139, 2268-2269.	1.4	6
1158	The treatment of severe falciparum malaria. BMJ: British Medical Journal, 1985, 291, 1573-1573.	2.3	5
1159	Synergy of antithrombin III concentrate and antivenom in preventing coagulopathy in a rat model of Malayan pit viper envenoming. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 880-884.	1.8	5
1160	Pseudomonas pseudomallei and sudden unexplained death in Thai construction workers. Lancet, The, 1990, 336, 1257-1258.	13.7	5
1161	Tough test for malaria vaccine. Lancet, The, 1994, 344, 1172-1173.	13.7	5
1162	The effect of plasma free fatty acids and long-chain triglycerides on glucose metabolism in uncomplicated falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1995, 89, 511-515.	1.8	5
1163	Naturally acquired immunity to vivax malaria. Lancet, The, 1999, 354, 162.	13.7	5
1164	Oral quinine pharmacokinetics and dietary salt intake. European Journal of Clinical Pharmacology, 2001, 57, 111-113.	1.9	5
1165	THE LIMITS OF LATE-COLONIAL INTERVENTION. Indonesia and the Malay World, 2008, 36, 429-449.	0.9	5
1166	Cerebrospinal Fluid HIV-1 Viral Load During Treatment of Cryptococcal Meningitis. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 668-669.	2.1	5
1167	An improved formulation of chloroquine for intramuscular administration: absorption kinetics in rabbits. Journal of Pharmacy and Pharmacology, 2011, 41, 726-728.	2.4	5
1168	â€~Ferry off the Mersey': The Business and the Impact of Decolonization in Liverpool. History, 2011, 96, 188-204.	0.1	5
1169	The effects of serum lipids on the in vitro activity of lumefantrine and atovaquone against Plasmodium falciparum. Malaria Journal, 2012, 11, 177.	2.3	5
1170	The Settlement of Decolonization and Post-Colonial Economic Development. Bijdragen Tot De Taal-, Land- En Volkenkunde, 2017, 173, 208-241.	0.1	5

#	Article	IF	CITATIONS
1171	Ceftriaxone Absorption Enhancement for Noninvasive Administration as an Alternative to Injectable Solutions. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	5
1172	Development of Rectodispersible Tablets and Granulate Capsules for the Treatment of Serious Neonatal Sepsis in Developing Countries. Journal of Pharmaceutical Sciences, 2019, 108, 2805-2813.	3.3	5
1173	Pooled Multicenter Analysis of Cardiovascular Safety and Population Pharmacokinetic Properties of Piperaquine in African Patients with Uncomplicated Falciparum Malaria. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	5
1174	Genome-wide microsatellite characteristics of five human Plasmodium species, focusing on Plasmodium malariae and P. ovale curtisi. Parasite, 2020, 27, 34.	2.0	5
1175	Randomized Controlled Trial of the Electrocardiographic Effects of Four Antimalarials for Pregnant Women with Uncomplicated Malaria on the Thailand-Myanmar Border. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
1176	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	5
1177	Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; protocol for a randomised, placebo-controlled prophylaxis study (COPCOV). Wellcome Open Research, 0, 5, 241.	1.8	5
1178	A cautionary note on the use of unsupervised machine learning algorithms to characterise malaria parasite population structure from genetic distance matrices. PLoS Genetics, 2020, 16, e1009037.	3.5	5
1179	Nonlinear Mixed-Effects Modelling of In Vitro Drug Susceptibility and Molecular Correlates of Multidrug Resistant Plasmodium falciparum. PLoS ONE, 2013, 8, e69505.	2.5	5
1180	Ex-Vivo Cytoadherence Phenotypes of Plasmodium falciparum Strains from Malian Children with Hemoglobins A, S, and C. PLoS ONE, 2014, 9, e92185.	2.5	5
1181	Methaemoglobinaemia and the radical curative efficacy of 8â€aminoquinoline antimalarials. British Journal of Clinical Pharmacology, 2022, 88, 2657-2664.	2.4	5
1182	The fragmented COVID-19 therapeutics research landscape: a living systematic review of clinical trial registrations evaluating priority pharmacological interventions Wellcome Open Research, 0, 7, 24.	1.8	5
1183	Prophylaxis for contacts of melioidosis. Journal of Infection, 1990, 21, 222-223.	3.3	4
1184	Glucose tolerance in pregnant patients with acute falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 666-667.	1.8	4
1185	Mefloquine prophylaxis. Lancet, The, 1993, 342, 551.	13.7	4
1186	Therapeutic effects of antivenom supplemented by antithrombin III in rats experimentally envenomated with Russell's viper (Daboia russelli siamensis) venom. Toxicon, 1995, 33, 77-82.	1.6	4
1187	Dosage for malaria treatment. Lancet, The, 1996, 348, 1312.	13.7	4
1188	The Treatment of Chloroquine-Resistant Malaria. Tropical Doctor, 1999, 29, 176-179.	0.5	4

#	Article	IF	Citations
1189	Serum bactericidal and inhibitory titres in the management of melioidosis. Journal of Antimicrobial Chemotherapy, 2000, 45, 123-127.	3.0	4
1190	Malaria and amphetamine 'horse tablets' in Thailand. Tropical Medicine and International Health, 2003, 8, 17-18.	2.3	4
1191	Pediatric Trauma. Pediatric Emergency Care, 2004, 20, 412-417.	0.9	4
1192	Malaria misconceptions. Lancet, The, 2005, 365, 653.	13.7	4
1193	Editorial: Developing drugs for neglected diseases. Tropical Medicine and International Health, 2006, 11, 383-384.	2.3	4
1194	Feasibility of malaria elimination. Lancet, The, 2011, 377, 638.	13.7	4
1195	Responding to the evidence for the management of severe malaria. Tropical Medicine and International Health, 2011, 16, 1085-1086.	2.3	4
1196	A multi-stage random forest classifier for phase contrast cell segmentation., 2015, 2015, 3865-8.		4
1197	Limited Polymorphism of the Kelch Propeller Domain in Plasmodium malariae and P. ovale Isolates from Thailand. Antimicrobial Agents and Chemotherapy, 2016, 60, 4055-4062.	3.2	4
1198	Pharmacokinetic properties of intramuscular versus oral syrup paracetamol in Plasmodium falciparum malaria. Malaria Journal, 2016, 15, 244.	2.3	4
1199	"ls it essential that a steamship company's poster must have a ship?― Journal of Historical Research in Marketing, 2017, 9, 386-424.	0.4	4
1200	Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia. Malaria Journal, 2019, 18, 114.	2.3	4
1201	â€~Ungentlemanly capitalism': John Hay and Malaya, 1904–1964. Management and Organizational History, 2019, 14, 98-122.	0.7	4
1202	Economic considerations support C-reactive protein testing alongside malaria rapid diagnostic tests to guide antimicrobial therapy for patients with febrile illness in settings with low malaria endemicity. Malaria Journal, 2019, 18, 442.	2.3	4
1203	Cell-Free Hemoglobin Is Associated With Increased Vascular Resistance and Reduced Peripheral Perfusion in Severe Malaria. Journal of Infectious Diseases, 2019, 221, 127-137.	4.0	4
1204	The use of ultrasensitive quantitative-PCR to assess the impact of primaquine on asymptomatic relapse of Plasmodium vivax infections: a randomized, controlled trial in Lao PDR. Malaria Journal, 2020, 19, 4.	2.3	4
1205	Remote-Controlled and Pulse Pressure–Guided Fluid Treatment for Adult Patients with Viral Hemorrhagic Fevers. American Journal of Tropical Medicine and Hygiene, 2021, 104, 1172-1175.	1.4	4
1206	SERCAP: is the perfect the enemy of the good?. Malaria Journal, 2021, 20, 281.	2.3	4

#	Article	IF	Citations
1207	The cardiovascular effects of amodiaquine and structurally related antimalarials: An individual patient data meta-analysis. PLoS Medicine, 2021, 18, e1003766.	8.4	4
1208	The WHO guideline on drugs to prevent COVID-19: small numbers- big conclusions. Wellcome Open Research, 2021, 6, 71.	1.8	4
1209	Preface to the Twenty-Third Edition. , 2014, , xi.		4
1210	Assessment <i>In Vitro</i> of the Antimalarial and Transmission-Blocking Activities of Cipargamin and Ganaplacide in Artemisinin-Resistant <i>Plasmodium falciparum</i> Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0148121.	3.2	4
1211	Contribution of genetic factors to high rates of neonatal hyperbilirubinaemia on the Thailand-Myanmar border. PLOS Global Public Health, 2022, 2, e0000475.	1.6	4
1212	Loading dose in antimalarial prophylaxis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, 79, 742.	1.8	3
1213	Diagnosis of melioidosis by means of an ELISA detecting antibodies toPseudomonas pseudomallei exotoxin. Preliminary assay evaluation. World Journal of Microbiology and Biotechnology, 1991, 7, 29-36.	3.6	3
1214	Summary of discussion and conclusions. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1994, 88, 63-65.	1.8	3
1215	Melioidosis. Zentralblatt Fur Bakteriologie: International Journal of Medical Microbiology, 1994, 280, 439-443.	0.5	3
1216	Evidence for continued two-brood replication of Plasmodium falciparum in vivo during quinine treatment. Acta Tropica, 2003, 89, 41-45.	2.0	3
1217	Modelling Malaria Control. PLoS Medicine, 2006, 3, e111.	8.4	3
1218	Modulating effects of plasma containing anti-malarial antibodies on in vitro anti-malarial drug susceptibility in Plasmodium falciparum. Malaria Journal, 2010, 9, 326.	2.3	3
1219	Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria. Journal of Pharmacy and Pharmacology, 2012, 64, 1603-1613.	2.4	3
1220	Introducing the concept of a new pre-referral treatment for severely ill febrile children at community level: a sociological approach in Guinea-Bissau. Malaria Journal, 2014, 13, 50.	2.3	3
1221	Reversibility of Retinal Microvascular Changes in Severe Falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2014, 91, 493-495.	1.4	3
1222	Drugs that reduce transmission of falciparum malaria. Lancet Infectious Diseases, The, 2018, 18, 585-586.	9.1	3
1223	Polymorphic markers for identification of parasite population in Plasmodium malariae. Malaria Journal, 2020, 19, 48.	2.3	3
1224	Reply to Aung et al. Clinical Infectious Diseases, 2021, 72, 536-538.	5.8	3

#	Article	IF	CITATIONS
1225	Development of weight and age-based dosing of daily primaquine for radical cure of vivax malaria. Malaria Journal, 2021, 20, 366.	2.3	3
1226	Detection of diverse Wolbachia 16S rRNA sequences at low titers from malaria vectors in Kayin state, Myanmar. Wellcome Open Research, 2019, 4, 11.	1.8	3
1227	Lumefantrine attenuates Plasmodium falciparum artemisinin resistance during the early ring stage. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 186-190.	3.4	3
1228	Natural Wolbachia infections in malaria vectors in Kayin state, Myanmar. Wellcome Open Research, 2019, 4, 11.	1.8	3
1229	Nitrofurantoin and glucose-6-phosphate dehydrogenase deficiency: a safety review. JAC-Antimicrobial Resistance, 2022, 4, dlac045.	2.1	3
1230	Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2022, 112, 824-835.	4.7	3
1231	Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry. Malaria Journal, 2022, 21, .	2.3	3
1232	Excess mortality attributable to hospital-acquired antimicrobial-resistant infections: a two-year prospective surveillance study in Northeast Thailand. Open Forum Infectious Diseases, 0, , .	0.9	3
1233	Complications of Malaria. Tropical Doctor, 1984, 14, 191-191.	0.5	2
1234	Management of severe malarial infection. Indian Journal of Pediatrics, 1989, 56, 155-163.	0.8	2
1235	Treatment and prophylaxis of falciparum malaria. Journal of Antimicrobial Chemotherapy, 1990, 26, 728-729.	3.0	2
1236	Melioidosis and laboratory safety. Journal of Hospital Infection, 1992, 22, 333-334.	2.9	2
1237	Quinine for children with severe and complicated malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1992, 86, 571-572.	1.8	2
1238	Antithrombin III and antivenom reversal of coagulopathy in rats envenomated with Malayan pit viper venom. Toxicon, 1994, 32, 97-103.	1.6	2
1239	Smoking cheroots reduces birthweight. Lancet, The, 1998, 352, 1521-1522.	13.7	2
1240	Randomised trial of azithromycin versus ofloxacin for the treatment of Typhoid feVer in adult. Medical Journal of Indonesia, 0, 7, 202.	0.5	2
1241	Antifungal susceptibilities of Cryptococcus neoformans in north-east Thailand. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1999, 93, 96-97.	1.8	2
1242	Retinal haemorrhage in P falciparum malaria. Lancet, The, 2002, 360, 515.	13.7	2

#	Article	IF	CITATIONS
1243	UK recommendations for severe malaria are worrying. BMJ: British Medical Journal, 2007, 334, 490.1-490.	2.3	2
1244	Global extent of chloroquine-resistant Plasmodium vivax – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 630-631.	9.1	2
1245	Quality controls for antimicrobial disk diffusion testing on <i>Leptospira</i> Vanaporn Wuthiekanun agar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 673-675.	1.8	2
1246	Does reduced oxygen delivery cause lactic acidosis in falciparum malaria? An observational study. Malaria Journal, 2019, 18, 97.	2.3	2
1247	Pharmacokinetic-Pharmacodynamic Modelling of Systemic IL13 Blockade by Monoclonal Antibody Therapy: A Free Assay Disguised as Total. Pharmaceutics, 2021, 13, 519.	4.5	2
1248	WHO COVID-19 therapeutic guidelines – Authors' reply. Lancet, The, 2021, 398, 118.	13.7	2
1249	Thinking Outside †The Box': Decolonization and Containerization. Palgrave Studies in Maritime Economics, 2019, , 67-99.	0.4	2
1250	Antimicrobial resistance in commensal opportunistic pathogens isolated from non-sterile sites can be an effective proxy for surveillance in bloodstream infections. Scientific Reports, 2021, 11, 23359.	3.3	2
1251	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	2
1252	Antiparasitic Drugs in Children. Clinical Pharmacokinetics, 1989, 17, 138-155.	3.5	1
1253	Estimating Plasmodium vivax parasitaemia. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1998, 92, 176.	1.8	1
1254	Modes d'action et caractéristiques pharmacologiques des antipaludiques. Médecine Et Maladies Infectieuses, 1999, 29, S307-S315.	5.0	1
1255	The Verbosity Epidemic. Science, 2008, 320, 1718-1718.	12.6	1
1256	Artesunate for severe malaria in African children – Authors' reply. Lancet, The, 2011, 377, 1154.	13.7	1
1257	Timing of Enteral Feeding in Cerebral Malaria in Resource-Poor Settings: A Randomized Trial. Journal of Infection, 2011, 63, e101.	3.3	1
1258	Reply to Cunnington et al. Journal of Infectious Diseases, 2013, 207, 370-371.	4.0	1
1259	Preliminary pharmaceutical development of antimalarial–antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas. International Journal of Pharmaceutics, 2014, 468, 55-63.	5.2	1
1260	Malaysia. The New Economic Policy in Malaysia: Affirmative action, ethnic inequalities and social justice Edited by Edmund Terence Gomez and Johan Saravanamuttu Singapore: NUS Press. 2013. Pp. xviiiÂ+Â393. Map, Notes, Index Journal of Southeast Asian Studies, 2015, 46, 155-158.	0.1	1

#	Article	IF	CITATIONS
1261	Identifying Malaria Hot Spots. Journal of Infectious Diseases, 2017, 216, 1051-1052.	4.0	1
1262	Optimal Duration of Follow-up for Assessing Antimalarial Efficacy in Pregnancy: A Retrospective Analysis of a Cohort Followed Up Until Delivery on the Thailand–Myanmar Border. Open Forum Infectious Diseases, 2019, 6, ofz264.	0.9	1
1263	A Temporizing Solution to "Artemisinin Resistance― New England Journal of Medicine, 2019, 381, 989-990.	27.0	1
1264	Economic Opportunity and Strategic Dilemma in Colonial Development: Britain, Japan and Malaya's Iron Ore, 1920s to 1950s. International History Review, 2020, 42, 424-446.	0.4	1
1265	Melioidosis and Glanders. , 2020, , 619-622.		1
1266	Time-to-death is a potential confounder in observational studies of blood transfusion in severe malaria. Lancet Haematology,the, 2021, 8, e12.	4.6	1
1267	Development and Validation of an <i>In Silico</i> Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
1268	Letter to the editor RE: Reuling etÂal., 2018 †liver injury in uncomplicated malaria is an overlooked phenomenon: An observational study'. EBioMedicine, 2021, 68, 103377.	6.1	1
1269	Bactericidal activities and post-antibiotic effects of ofloxacin and ceftriaxone against drug-resistant Salmonella enterica serovar Typhi. Journal of Antimicrobial Chemotherapy, 2021, 76, 2606-2609.	3.0	1
1270	Malaria Diagnosis and Treatment. , 2008, , 303-321.		1
1271	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Research, 0, 6, 216.	1.8	1
1272	Falciparum malaria mortality in sub-Saharan Africa in the pretreatment era. Trends in Parasitology, 2021, , .	3.3	1
1273	Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity. Clinical Pharmacology and Therapeutics, 2022, 111, 676-685.	4.7	1
1274	Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study. Frontiers in Cellular and Infection Microbiology, 2022, 12, 804470.	3.9	1
1275	Comparison of antibody responses and parasite clearance in artemisinin therapeutic efficacy studies in Democratic Republic of Congo and Asia. Journal of Infectious Diseases, 0, , .	4.0	1
1276	Arteritis of the arms BMJ: British Medical Journal, 1981, 282, 1663-1663.	2.3	0
1277	Glucose and insulin homeostasis during the Jarisch-Herxheimer reaction. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1985, 79, 74-77.	1.8	0
1278	Quinine and Severe Falciparum Malaria in Late Pregnancy. Obstetrical and Gynecological Survey, 1986, 41, 157.	0.4	0

#	Article	IF	Citations
1279	Schizontocidal antimalarials: a reply. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1990, 84, 610.	1.8	0
1280	Effects of dopamine and adrenaline infusions in severe infection. Lancet, The, 1996, 348, 1100.	13.7	0
1281	Artemether in Severe Malaria. New England Journal of Medicine, 1996, 335, 1922-1924.	27.0	0
1282	Practice of clinical medicine in the tropics. Lancet, The, 1997, 349, S6-S7.	13.7	0
1283	Resistance to antimicorbial agents in Salmonella typhi in Vietnam: clinical response to therapy and molecular mechanisms. Medical Journal of Indonesia, 0, 7, 184.	0.5	0
1284	Quantitative bacteriology of Typhoid fever in Vietnam. Medical Journal of Indonesia, 0, 7, 274.	0.5	0
1285	Serum antibody response in patients with mild Typhoid fever from southern Vietnam. Medical Journal of Indonesia, 1998, 7, 269.	0.5	0
1286	Southeast Asia - Capital and Entrepreneurship in South-East Asia. By Rajeswary Ampalavanar Brown. New York: St. Martin's Press, Houndmills: Macmillan Press, 1994. Pp. xiv, 302. Tables, Maps, Index, Bibliography Journal of Southeast Asian Studies, 1999, 30, 156-158.	0.1	0
1287	South-East Asia - Edmund Terence Gomez: Chinese business in Malaysia: accumulation, accommodation and ascendance. xxi, 234 pp. Richmond, Surrey: Curzon, 1999. £40 Bulletin of the School of Oriental and African Studies, 2000, 63, 455-456.	0.0	0
1288	REVIEWS Britannia's Empire: Making a British World By Bill Nasson, Stroud, UK: Tempus, 2004. ISBN: 0 7524 2958 2. £20 (hardback) Journal of Global History, 2006, 1, 152-152.	0.9	0
1289	Authors' Reply: Response to Ian Clark. PLoS Medicine, 2006, 3, e69.	8.4	0
1290	The British Occupation of Indonesia, 1945–1946: Britain, the Netherlands and the Indonesian Revolution. By Richard Mcmillan. pp. xi, 248. London, RoutledgeCurzon for the Royal Asiatic Society, 2006 Journal of the Royal Asiatic Society, 2007, 17, 360-362.	0.1	0
1291	Managing British colonial and post-colonial development: the Crown Agents, 1914–1974 – By David Sunderland. Economic History Review, 2008, 61, 509-510.	0.9	0
1292	Copper empire: mining and the colonial state in Northern Rhodesia, c.193064 By Larry J. Butler. Economic History Review, 2008, 61, 758-759.	0.9	0
1293	The spread of antimalarial drug resistance: A mathematical model with practical implications for ACT drug policies. Nature Precedings, 2008, , .	0.1	0
1294	Malarial Retinopathy in Adults. Journal of Infection, 2011, 63, 494-495.	3.3	0
1295	Optimal sampling designs for accurate estimation of parasite clearance in the context of artemisinin resistance. Malaria Journal, 2012, 11, P39.	2.3	0
1296	Bloodstream infections in south and southeast Asia – Authors' reply. Lancet Infectious Diseases, The, 2013, 13, 15.	9.1	0

#	Article	IF	CITATIONS
1297	Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. Journal of Antimicrobial Chemotherapy, 2013, 68, 1695-1695.	3.0	0
1298	Rectal pH in Well and Unwell Infants. Journal of Tropical Pediatrics, 2013, 59, 162-162.	1.5	0
1299	Melioidosis and Glanders., 2013, , 580-583.		0
1300	Malaysia@50: Economic Development, Distribution, Disparities. ByJomo Kwame Sundaram andWee Chong Hui. Singapore: World Scientific Publishing, 2014. xvi + 198 pp. Tables, figures, glossary, bibliography, notes, index. Cloth, \$85.00. ISBN: 978-981-4571-38-8 Business History Review, 2015, 89, 399-401.	0.4	0
1301	Artemisinin resistance in Myanmar – Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 1002-1003.	9.1	0
1302	Promises and Predicaments. Trade and Entrepreneurship in Colonial and Independent Indonesia in the 19th and 20th Centuries, edited by Alicia Schrikker and Jeroen Touwen. Bijdragen Tot De Taal-, Land- En Volkenkunde, 2016, 172, 586-588.	0.1	0
1303	Trade and Empire in Early Nineteenth entury Southeast Asia: Gillian Maclaine and his Business Network. By G.ÂRoger Knight. Boydell. 2015. xiv + 193pp. £65.00 History, 2017, 102, 321-322.	0.1	0
1304	The Development of Qinghaosu (Artemisinin)—A View From the Outside. , 2018, , xi-xii.		0
1305	The Politics and Economics of Decolonization in Africa: The Failed Experiment of the Central African Federation. By AndrewÂCohen. I. B. Tauris. 2017. viii + 300pp. £75.00 History, 2019, 104, 792-793.	0.1	0
1306	Sarah Stockwell. The British End of the British Empire. Cambridge: Cambridge University Press, 2018. Pp. 335. \$99.99 (cloth) Journal of British Studies, 2019, 58, 872-874.	0.0	0
1307	Primaquine for Plasmodium vivax malaria treatment – Authors' reply. Lancet, The, 2020, 395, 1972.	13.7	0
1308	COVID-19 chemoprevention. International Journal of Infectious Diseases, 2021, 107, 31-33.	3.3	0
1309	Good participatory practice for coronavirus disease 2019 (COVID-19) research: the case of a COVID-19 prevention study. Wellcome Open Research, 0, 6, 216.	1.8	0
1310	Antimalarial Agents. Infectious Disease and Therapy, 2007, , 379-410.	0.0	0
1311	CMCH and MORU: A Highly Successful Collaboration. Journal of Chittagong Medical College Teachers Association, 2010, 20, 2-5.	0.0	0
1312	Letter to the Editor. Tropical Medicine and International Health, 1998, 3, 249-249.	2.3	0
1313	Questioning the Claimed Superiority of Malaria Parasite Ex Vivo Viability Reduction Over Observed Parasite Clearance Rate?. Journal of Infectious Diseases, 2021, 224, 738-739.	4.0	O
1314	Survival of Burkholderia pseudomallei and Pathogenic Leptospira in Cola, Beer, Energy Drinks, and Sports Drinks. American Journal of Tropical Medicine and Hygiene, 2020, 103, 249-252.	1.4	0

#	Article	IF	CITATIONS
1315	Severe malaria, Pascalian therapeutics and the US FDA. Clinical Infectious Diseases, 2022, , .	5.8	O
1316	Title is missing!. , 2020, 16, e1009037.		0
1317	Title is missing!. , 2020, 16, e1009037.		0
1318	Title is missing!. , 2020, 16, e1009037.		0
1319	Title is missing!. , 2020, 16, e1009037.		0
1320	Title is missing!. , 2020, 17, e1003393.		0
1321	Title is missing!. , 2020, 17, e1003393.		0
1322	Title is missing!. , 2020, 17, e1003393.		0
1323	Title is missing!. , 2020, 17, e1003393.		0
1324	Title is missing!. , 2020, 17, e1003393.		0